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Abstract
The first trimester of pregnancy is a dynamic time of change involving the implantation
and development of the fetus, together with a wide range of related endocrine
changes arising from the ovary and feto-placental unit, as well as other changes in
maternal and fetal physiology. The present longitudinal study has investigated two
main areas of endocrinology in circulating maternal serum from positive pregnancy
test to the detection of a fetal heartbeat, namely (i) AMH and (ii) thyroid function.
Women attending Fertility North and conceiving during fertility investigation or
treatment underwent phlebotomy twice weekly and AMH, TSH, fT3 and fT4 levels
were measured, in addition to the reproductive hormones oestradiol (E2),
progesterone (P4) and human chorionic gonadotropin (hCG).
AMH is a well-established biomarker for assessing the age-related decline of the
oocyte pool in healthy women, but has many other clinical uses including the
assessment of polycystic ovary syndrome (PCOS), estimating response to ovarian
stimulation with exogenous gonadotrophins, detection of granulosa cell tumours and
identification of premature ovarian insufficiency. AMH also influences follicle growth,
but the precise mechanism by which it does this is unknown and its role during
pregnancy has not been adequately characterised.
In this study the key findings regarding AMH were the differences between pre-
ovulatory and luteal phase AMH levels in pre pregnant women and the three distinct
patterns of changing AMH noted in women once pregnancy was confirmed. Prior to
pregnancy, mean AMH levels peaked at time of ovulation (gestation week 2) and then
dropped at mid-luteal phase (gestation week 3). 86.1% of women had their maximum
AMH level at or before ovulation, with 13.9% of women having their maximum AMH at
mid-luteal phase. However, once pregnancy was achieved, AMH levels for each woman
did not remain constant, but moved significantly away from their first non-pregnant
measurement, with a trend in viable pregnancies of an AMH level that either
consistently increased or decreased from gestation week 4 (time of first positive hCG
measurement) through to week 7. The difference between women with rising AMH
compared to those with falling AMH significantly increased (p=0.000) during early
pregnancy. In general terms women with rising AMH levels, had continually rising AMH
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levels and these levels became increasingly divergent from those women who had
falling AMH levels and whose AMH levels continued to decrease. In contrast, AMH
levels in women with non-viable pregnancies were very inconsistent, with no definitive
rising or falling trend observed. Instead, AMH levels in women with non-viable
pregnancies showed erratic and sporadic changes, both rising and falling in the same
individual from gestation weeks 4 to 7. There was a significant negative correlation
between baseline (day 2 of the menstrual cycle) AMH and patient age (r=-0.507,
p=0.000). No associations were observed between AMH and patient body mass index
(BMI), stimulation medications (follicle stimulating hormone dose), treatment type or
fetal sex. There were weak negative correlations between AMH and P4 (r=-0.220,
p=0.000,) and TSH (r=-0.155, p=0.001), but not E2, hCG, fT3 or fT4. This study was not
designed to determine causative factors for the AMH changes observed and further
investigations would be required to address possible causes of these reported
changes.
The importance of normal maternal thyroid function in pregnancy and fetal
development is well characterised and thyroid dysfunction can result in adverse effects
on the unborn child, including a higher risk of miscarriage. Throughout the first
trimester, the fetus is dependent on maternal thyroxine as the fetal thyroid is not fully
functional until approximately gestation week 16. Despite this important role, the
changes, if any, occurring during this vibrant period are poorly documented and often
are limited to cross-sectional sampling.
In this study the key findings regarding thyroid function were of stable fT3, fT4 and TSH
levels between gestation weeks 0 to 4 (pre pregnancy) with subsequent changes in
thyroid function once pregnancy was established at gestation week 4 (hCG
>25mU/ml). From gestation weeks 4 to 6.5 some significant changes in thyroid
hormone levels were observed with a gradual decrease in fT3 (r=-0.104, p=0.005) and
TSH levels (r=-0.123 p=0.013). In contrast, fT4 levels remained constant during early
pregnancy (gestation weeks 4 to 6.5). No markers of thyroid function appeared to
affect pregnancy outcome. Despite TSH levels ranging from 0.27 - 4.93mU/L, only 6
patients (7.0%) had TSH levels >4.0mU/L, of whom only 3 (3.5%) miscarried. Reference
ranges were calculated for fT3, fT4 and TSH for gestation weeks 4 to 6.5 and were
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found to be comparable to later first trimester ranges reported in other studies. There
were two patients who tested positive for thyroid peroxidase antibody (TPOAb) who
were excluded from the study (both were viable pregnancies with normal thyroid
hormone levels).
In summary, this study was able to directly follow the changes in AMH and thyroid
hormone levels within the same individual over time, resulting in the identification of
unique changes in very early pregnancy.
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CHAPTER 1
INTRODUCTION
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1 Introduction
A human pregnancy is a time of dynamic physiological change, and its success relies on
the correct balance of hormones to support and maintain the growing fetus. Extensive
research investigating these hormones has allowed clinicians to increase women’s
chances of conceiving and maintaining a pregnancy, by closely monitoring these
changes and providing supportive care to improve the pregnancy outcome.
There are a growing number of couples who rely on assisted reproductive technology
(ART) in order to conceive. There were 61,158 ART cycles performed in Australia in
2011, representing an increase of 8.3% over the previous year [1]. Couples are having
children later in their lives and this can have a detrimental effect on their ability to
conceive [2]. A woman’s fertility starts to decrease from her early twenties and, as a
result, many women are diagnosed with fertility issues when they begin trying to
conceive. The median age of all mothers who gave birth to their first child was 28.9
years in 1993, rising to 29.5 years in 1998 and 30.8 years in 2013 [3]. Unfortunately,
postponing childbirth to an age at which female reproductive capacity is reduced often
leads to involuntary childlessness. In addition to an increased number of women
having difficulties conceiving, there are also a large percentage of miscarriages or
pregnancy losses during early gestation. Although there are many factors which can
contribute to an increased risk of miscarriage, such as higher age, smoking and pre-
existing medical conditions, a large number of pregnancy losses remain unexplained
[4].
The monitoring of reproductive hormones in pregnancy is a useful tool for identifying
women who may benefit from therapeutic interventions, for example progesterone
supplementation to reduce the risk of miscarriage [5]. This is particularly relevant in
patients undertaking IVF where the ovaries are manipulated via exogenous hormones
to stimulate the uterus and support the pregnancy in the early stages [5]. Thyroid
disorders have a great impact on pregnancy outcome, however monitoring of these
hormones in early pregnancy is not routine due to the low percentage of women that
are affected.
21
Routine reproductive hormone assays form part of a patient’s treatment at Fertility
North and these blood samples were further analysed to detect any changes in AMH
and thyroid hormone levels during early pregnancy, in addition to the monitoring of
the standard reproductive hormone levels (E2, P4 and hCG). Normal reference ranges
for thyroid hormones fT3, fT4 and TSH were established for gestation weeks 4 to 7.
1.1 The Female Reproductive System
1.1.1 Folliculogenesis
The main components of the female reproductive system are the gonads (ovaries) and
uterus. The primary functions of the ovaries are to produce mature oocytes in a
process termed oogenesis, and produce hormones to prepare the uterus for
incubation of one or more embryos [6-8].
The follicles are the primary functional units of the ovaries. In a developing embryo,
germ cells populate the ovary and begin forming primordial follicles, which are
comprised of small, non-growing functionally immature oocytes surrounded by a single
layer of squamous granulosa cells [9]. Development of primordial follicles begins half
way through gestation and completes shortly after birth, when there are
approximately one million primordial follicles in each ovary [10, 11].
As women mature, their primordial follicles are released from dormancy and are
recruited to the growing follicle pool, of which only about 400 will mature and ovulate
[11]. The majority of a woman’s follicles will degenerate prior to puberty at
approximately 10-11 years of age, by a process called atresia [12]. Once a follicle is
recruited, it goes through various stages of growth and development necessary for
ovulation and potential fertilisation and this is termed folliculogenesis. Folliculogenesis
is characterised by the proliferation and differentiation of granulosa and theca cells
[13].
The pre-antral stage of folliculogenesis commences at puberty, when a cohort of
primordial follicles is recruited during each menstrual cycle and the granulosa cells
undergo rapid proliferation. Pre-antral follicles grow to between 0.1–0.2 mm in
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diameter, are not regulated by gonadotrophins and have limited capacity for hormonal
production. Instead, oocyte-derived growth factors including two members of the
transforming growth factor (TGF)β super family, growth and differentiation factor 9
(GDF9) and bone morphogenetic protein 15 (BMP15) have been implicated in the
regulation of early follicle growth [14, 15].
The antral stage of follicular development is characterised by follicles growing to 0.2 -
0.4mm in diameter [13]. This phase of follicle recruitment is dependent on the
hypothalamic–pituitary–gonadal endocrine axis [16]. The granulosa cells at this stage
develop receptors for follicle-stimulating hormone (FSH) and oestrogen, while the
thecal cells develop receptors for luteinizing hormone (LH) [13, 17]. Most of the
growing follicles will undergo atresia, unless they are rescued by FSH [18-20]. Among
the group of rescued follicles, usually only one follicle is selected to become the
dominant follicle. This follicle is characterized by a fluid-filled cavity or antrum and is
called an antral or Graafian follicle [13]. One study postulated that the future dominant
follicle contains more granulosa cells and therefore FSH receptors, making it more
sensitive to FSH, compared with the remaining subordinate follicles that become
atretic [21]. This dominant follicle will then release its oocyte at ovulation under the
influence of LH [22]. The cyclic recruitment of follicles continues until the growing
follicle pool is exhausted, folliculogenesis ceases and this time coincides with the onset
of menopause.
1.1.2 Reproductive Hormones in the Menstrual Cycle and Pregnancy
The menstrual cycle describes the changes that occur in the uterus and ovary that
enable a fertile female to reproduce. Menarche is the term used to describe a female’s
first menstrual cycle, which usually occurs around the age of 12 [23]. The menstrual
cycle can vary in length, but on average takes 28 days [24] and is regulated by a
complex interplay of endocrine factors and hormones that results in ovulation and the
maintenance of an embryo through to a foetus if there is a successful fertilisation.
In the absence of an implanted embryo, the endometrium undergoes apoptosis and
sheds its inner lining. This stage of the menstrual cycle is termed menses and this
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menstrual fluid is composed of inflammatory exudate, red blood cells, and proteolytic
enzymes [25]. This ‘bleeding’ typically takes around four days and marks the start of
each menstrual cycle [26]. The proliferative phase of the menstrual cycle lasts on
average fourteen days and is characterised by the build-up of the stratum functionalis
of the endometrium of the uterus, driven by follicle growth and recruitment in the
ovary [25]. Increasing amounts of oestrogen are secreted by growing follicles, resulting
in a negative feedback on FSH secretion from the pituitary gland [27].
Gonadotrophin‐releasing hormone (GnRH) is secreted by the hypothalamus which
triggers the anterior pituitary to release LH and FSH. These hormones work in
conjunction with each other to stimulate follicle development, assist in their
recruitment and maturation and contribute to the production of oestrogen and
triggering the final release of the egg from the ovary [28]. It is thought that ovulation,
which occurs around day 14-15 of the menstrual cycle, occurs due to an increased
release of GnRH, causing a surge in LH [29]. The remnants of the follicular granulosal
and thecal cells after the oocyte is released, form the corpus luteum (CL) in the ovary
[30].
The luteal phase of the menstrual cycle occurs approximately from days 14-28 and
during this time, the CL is responsible for secreting the hormones progesterone and
oestrogen, along with relaxin and inhibin [31-33]. The release of progesterone triggers
stromal differentiation and stimulates glandular secretions in conjunction with the
build-up of basal vacuoles in the glandular epithelium to provide an environment that
will maintain early embryonic development [34].
Once the CL has matured and reached its maximal potential for secretion of
progesterone, luteal function is maintained for a few days and then if fertilisation of an
oocyte and implantation of the resulting embryo does not occur, the CL regresses to
become the corpus albicans, causing a drop in oestrogen and progesterone levels [30].
The unfertilised egg passes through the uterus during menses and the cycle begins
again.
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If implantation occurs, the trophoblast cells of the resultant embryo release human
chorionic gonadotrophin (hCG) which directly stimulates the CL to continue to secrete
progesterone and oestrogen and sustain the pregnancy for approximately the first
three months, until the placenta takes over in synthesising and releasing these
hormones [35]. A positive pregnancy can usually be determined at about gestation
week 4, when a blood or urine test detects the presence of hCG, indicating a
successfully implanted blastocyst and commencement of embryogenesis [36].
1.2 Anti-Müllerian Hormone (AMH)
1.2.1 AMH Physiology and Ovarian Function
AMH is a member of the transforming growth factor β family of peptide growth and
differentiation factors [37] and is produced by granulosa cells of small ovarian follicles
[38]. AMH plays an essential role in ovarian folliculogenesis, by inhibiting the
recruitment of primordial follicles into the pool of growing follicles and decreasing the
responsiveness of growing follicles to FSH [39].
AMH is expressed in the growing follicles of the ovary until they have reached the size
and stage for dominant selection [40]. AMH expression in a follicle peaks once it
reaches the preantral and small antral stages, then gradually diminishes as follicles
grow to the larger antral and preovulatory stages [41].
1.2.2 AMH  in a Woman’s Life Cycle
AMH levels throughout a woman’s life are strongly correlated with the different stages
of follicle development and the numbers of non-growing follicles. One study [42]
measured AMH levels in healthy females from birth to the end of their reproductive
life. At birth, AMH levels were undetectable, followed by a small increase in the levels
a few weeks after birth. This was then followed by a gradual increase in AMH levels
during childhood until early adolescence, reaching a maximum level at 15.8 years old.
Thereafter, AMH levels remained stable until a woman reached her early 20s, and then
from the age of 25 years, AMH levels progressively declined throughout a woman’s
reproductive life until menopause.
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1.2.3 AMH as a Marker of Ovarian Reserve and Ovarian Response in Assisted
Reproduction
Serum AMH concentrations have been correlated with the number of antral follicles
present in the ovary, such that low levels of AMH can often indicate low ovarian
reserve whilst a high level may indicate polycystic ovary syndrome (PCOS) [43]. AMH
has been used as a predictor of ovarian responsiveness to exogenous gonadotrophins
in fertility treatments such as IVF,  being a better predictor than FSH, inhibin B or
oestradiol [44]. Many groups have since reported on the capacity of AMH to predict
ovarian response and/or IVF/ICSI cycle outcomes, being a better marker of ovarian
reserve than increasing age or antral follicle count (AFC) [45, 46]. Algorithms have
been devised showing the changing levels of AMH at different stages of life [47, 48].
However, this presumes that the levels are a function of the maturing and senescent
ovary, simply reflecting the ovarian reserve. Unfortunately, this is not the case and
production of AMH has now been shown to vary in differing physiological states when
the ovarian reserve is constant, such as during the menstrual cycle [49] and whilst
using the contraceptive pill [50].
1.2.4 AMH in PCOS
PCOS is the most common endocrine disorder in women of reproductive age [51] and
the primary cause of anovulatory infertility and  hyperandrogenism [52]. Women with
PCOS show markedly raised AMH levels compared to normoovulatory women [53, 54]
which is largely attributable to the increased number of small antral follicles in the
ovary and characteristics of the granulosa cells, resulting in anovulation [55]. AMH
levels are thought to be directly related to the severity of PCOS, with higher levels
indicating more problems in folliculogenesis and granulosa cell function [56].
1.2.5 AMH in Pregnancy
Despite extensive research into the roles of AMH in ovarian reserve, ovarian
responsiveness to gonadotrophin stimulation and pregnancy outcomes in assisted
reproductive methods, there are only a few studies on AMH levels during pregnancy
and the findings are inconsistent. The first investigation was a cross-sectional study
and only defined the subjects according to whether they were in the first, second or
third trimester of pregnancy [57]. There were no changes seen but it is likely that the
study design may have limited the likelihood of small changes being detected. AMH
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during pregnancy has been studied again more recently using a longitudinal design to
follow individual women, although again the sampling for each woman was only done
once in each of the three trimesters [58]. There was a significant reduction in AMH as
the pregnancy progressed, returning to baseline levels following delivery. A decline of
AMH levels in the first trimester was also noted in another cross sectional study [59].
However, neither of these studies was able to examine any possible changes in AMH
over the first few weeks of pregnancy when there are significant changes in the
hormonal milieu.
1.2.6 Effects of Contraceptive Pill on AMH
The combined oral contraceptive pill (COCP) has been used by women as an effective
means of preventing pregnancy for over four decades. A study in five European
countries estimated that over 22 million women use the COCP yearly [60]. The COCP is
comprised of synthetic oestrogen and progesterone which when taken in accordance
with the manufacturer’s directions, will suppress the hypothalamic-pituitary-ovarian
axis to inhibit ovulation [61], by preventing follicular growth and maturation and also
affecting the proliferation of the endometrium [62, 63].
The effect of taking the oral contraceptive pill on levels of AMH is debateable. In the
past, women have been tested for ovarian reserve whilst taking the oral contraceptive
pill, because AMH levels were thought to be unaffected [64-66]. However, there are
conflicting reviews that show AMH levels are reduced whilst taking oral contraception
[67-69] and increased after ceasing oral contraception [50]. This could indicate that
AMH levels are not only an indicator of remaining follicle numbers, but also that AMH
levels may be influenced by the state of follicles, which will be important to note when
measuring AMH levels during pregnancy when follicle growth is suppressed.
The COCP is often used in conjunction with a GnRH agonist in IVF cycles to improve the
outcome of controlled ovarian hyperstimulation and better time oocyte retrieval by
preventing a premature LH surge [70]. Oral contraceptive pre-treatment has been used
to improve the outcome in poor responders to ovarian stimulation by reducing the
amount of gonadotrophins and period of time required for ovarian stimulation [71,
72]. Oral contraception is also used to reduce the incidence of ovarian
hyperstimulation syndrome (OHSS) in high responders [73] and to avoid cyst formation
after agonist administration [74]. It will be important to note in the present study
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whether a patient has been taking oral contraception in their IVF or ICSI treatments, as
AMH levels may be influenced.
1.2.7 Basis for Investigating AMH in Early Pregnancy
FSH and LH are supressed in pregnancy to prevent ovulation and risk of multiple
conceptions [75]. FSH is important in development of the maturing follicle, including
the formation of AMH-releasing granulosa cells. Since there is thought to be no
follicular activity during pregnancy one might expect minimal changes in AMH. The
same principal should apply during OCP use when gonadotropins are supressed,
however there is evidence of a decrease in AMH levels [49]. There is also evidence that
ovarian follicular development is not completely inhibited during OCP use [76]. A
longitudinal study observed a decrease in AMH in each trimester during pregnancy and
stated that there is a reduced follicular maturation during pregnancy (and
consequently less AMH-producing follicles), however since AMH did not reach
undetectable levels, there is likely some follicular activity present during pregnancy
[58]. Therefore the benefit of this present longitudinal study investigating the changes
in serum AMH concentrations during pregnancy will hopefully gain further insight into
the possible changes in follicle growth and other factors that may affect AMH
expression.
1.3 Thyroid Hormones
1.3.1 Thyroid Function in Pregnancy
Under the influence of thyrotropin-releasing hormone (TRH) from the hypothalamus,
thyroid stimulating hormone (TSH), also known as thyrotropin, is secreted by
thyrotrope cells in the anterior pituitary gland, stimulating the thyroid gland to
produce T4 (thyroxine), which is then converted to T3 (triiodothyronine) - the active
hormone responsible for cell metabolism [77]. Maternal thyroid hormones play a
critical role in fetal development, since the fetal thyroid gland does not become a
functional until the second trimester. In pregnancy, increased maternal T4 levels are
vital to the developing fetus, particularly during embryonic and fetal nervous system
development in the first twelve weeks [78].
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TSH levels are known to decrease in pregnancy, particularly during the first trimester,
correlated with an increase in human chorionic gonadotropin (hCG) [79]. The decrease
in TSH is most likely due to a weak stimulatory effect of hCG on TSH receptors on the
thyroid. The most commonly accepted reason for TSH reducing slightly in the first
trimester is that there is homology between the alpha subunits of both TSH and hCG
[80]. As such, hCG can act on TSH receptors at the thyroid and stimulate them, thereby
increasing T4 and T3. This feeds back to the hypothalamus, decreasing TRH, TSH and,
in turn, decreasing T3 and T4 as part of the natural negative feedback loop. TSH is
therefore lowest when hCG is at its highest because hCG rises until 8-10 weeks of
pregnancy and then plateaus and starts falling when TSH starts recovering. Such
changes during pregnancy have resulted in the need for pregnancy-stage specific
reference ranges to prevent the misdiagnosis of disease [81-83].
All studies on the change in thyroid function tests in pregnancy are cross-sectional in
design, using blood obtained from pathology laboratories undertaking first trimester
screening [81]. Whilst providing practical guidance on the interpretation of clinical
screening tests, they do not describe the changes that may occur during early
pregnancy, nor are there established reference intervals at this time during pregnancy.
1.3.2 Thyroid Disease in Pregnancy
Thyroid disease is the second most common endocrine disorder affecting women of
reproductive age and when left untreated during pregnancy, can lead to a multitude of
adverse effects including an increased risk of miscarriage, placental abruption,
hypertensive disorders and fetal growth restriction [84].
Frank hypothyroidism, sometimes referred to as an underactive or low thyroid, is
characterized by a low fT4 and raised TSH levels. In contrast, subclinical or
asymptomatic hypothyroidism is characterized by slightly to moderately raised TSH
only and normal fT4 levels. The incidence of hypothyroidism during pregnancy is
approximately 0.3% to 0.5% and 2% to 3% for subclinical hypothyroidism [85]. Since
high maternal TSH levels are known to increase the risk of miscarriage in women with
subclinical hypothyroidism [86], this could be a contributing factor to supposedly
unexplained miscarriages in women not displaying any symptoms of thyroid
dysfunction.
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Hyperthyroidism occurs with an overactive thyroid. Primary hyperthyroidism results in
an increase of fT4 and fT3 and a suppressed TSH level, whereas subclinical
hyperthyroidism is a milder form of hyperthyroidism and is characterized by a
suppressed TSH level, but with a normal fT4 and fT3 level [87].
Graves' disease is the most common cause of hyperthyroidism. Hyperthyroidism
occurs in about 0.2% of pregnancies [85]. Subclinical hyperthyroidism is not thought to
be associated with adverse pregnancy outcomes [88] and therefore treatment is not
recommended.
1.3.3 Thyroid Autoimmunity in Pregnancy
Thyroid autoimmunity is characterized by the presence of antithyroid antibodies. Of
particular interest is the marker antithyroid peroxidase which is responsible for thyroid
hormone synthesis [89]. Approximately 10-20% of euthyroid women (having TSH
within a defined normal range) are positive for thyroid peroxidase antibody (TPOAb)
[90, 91], of which 16% will develop a TSH that exceeds 4.0mlU/L by the end of the third
trimester. About 50% of TPOAb positive women will develop postpartum thyroiditis,
which is a consequence of the immunological changes that occur during pregnancy
[92]. Therefore TPOAb  is a strong risk factor for thyroid dysfunction both during and
after pregnancy [93].
There is evidence that women who test positive for TPOAb during pregnancy tend to
have higher TSH levels, which may indicate a slight impairment of thyroid function [94-
97]. Numerous studies have reported that TPOAb positive women have an increased
risk of miscarriage [98-103] as well as an increased risk of preterm birth [104]. Thyroid
autoimmunity is associated with infertility [105], which may be attributed to a higher
prevalence of endometriosis in infertile women [101, 106]. The association between
thyroid autoimmunity and endometriosis is likely due to an autoimmune dysfunction
in the pathogenesis of both diseases, although the exact mechanisms are unknown.
There is evidence of increased secretion of pro-inflammatory cytokines and
compromised function of cell-mediated natural immunity in endometriosis [107].
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In summary, women who test positive for TPOAb should be excluded from thyroid
hormone studies, as these women may have higher TSH levels and a greater risk of
miscarriage. More importantly, inclusion of these women when calculating thyroid
reference intervals could result in falsely high values.
1.3.4 Thyroid Disease Screening, Diagnosis and Treatment in Pregnancy
Adequate treatment of thyroid conditions in pregnancy, particularly during early
gestation greatly minimises pregnancy risks and complications, resulting in significantly
improved outcomes and highlighting the need for correct diagnosis. Despite this need
for detection of thyroid dysfunction in pregnancy, diagnosis can prove challenging,
mainly due to reference interval variations between methods, but also due to varying
TSH levels at different stages of pregnancy, variations in TSH in different aged women
and between populations of different ethnicity [108].
There have been numerous studies aimed at determining reference intervals for
thyroid function in pregnancy using different assays [82, 97, 109-117], with
significantly variable results. One study that compared the reproducibility of thyroid
reference ranges in pregnant women between two different laboratories, observed up
to 100% of maternal fT4 levels fell outside the other group’s reference range despite
similar TSH levels [118]. This further emphasises the need for assay-specific pregnancy
reference ranges to minimise the misclassification of thyroid disease.
The symptoms of thyroid disease can often be mistaken for the usual symptoms of
pregnancy, making it even more challenging to identify. Furthermore, the 2012
Endocrine Society guidelines recommend screening only pregnant women at high risk
of thyroid disease, which includes women with a history of previous thyroid
dysfunction, goitre, positive thyroid antibodies, cervical irradiation, thyroid surgery,
family history of thyroid disease, presence of clinical signs or symptoms of
hypothyroidism, diagnosis of type 1 diabetes mellitus or any other autoimmune
disease, history of repeated abortions, prematurity, or infertility, morbid obesity,
treatment with lithium, amiodarone, living in an area with moderate to severe iodine
deficiency and also if a woman is over 30 years of age [103]. One study found that by
selectively screening only high-risk patients, 30% of those with subclinical
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hypothyroidism would be missed [119]. Despite this, another randomised controlled
trial of 4,562 women did not show a reduction in adverse outcomes in those who were
universally screened compared to case finding [120].
The clinical classification of thyroid dysfunction has been debated for over a decade.
Only recently has a general consensus been reached that the upper limit for TSH in
pregnancy is lower than in non-pregnant adults. A generally accepted upper reference
interval for TSH in the first trimester of pregnancy is an upper limit of 2.5 mIU/L [92].
Researchers have investigated the treatment and pregnancy outcomes of pregnant
women with TSH levels elevated above this cut-off range.  Treating thyroid antibody-
positive women with Levothyroxine results in a significant decrease in maternal and
neonatal complications [121]. One study group found that pregnant women with first-
trimester TSH levels between 2.5 and 5.0 mIU/litre were 70% more likely to have fetal
loss than euthyroid women [120]. Abalovich and colleagues [122] showed that a
successful pregnancy wasn’t dependent on whether a hypothyroidism diagnosis was
overt or subclinical, but mainly on the treatment received.  Despite the known adverse
effects of thyroid disease during pregnancy, the prevalence of the disease is low and
further research is needed on pregnancy outcomes and treatment of women with
thyroid disease.
The issue of whether to perform systematic screening for thyroid hormones in
pregnancy remains largely controversial. Studies are now directing focus to the
consequences to the mother and unborn child of untreated subclinical hypothyroidism
and subclinical hyperthyroidism. Universally accepted reference ranges for thyroid
function tests during pregnancy are still needed. Until then, laboratories need to adapt
their own assay-dependent, gestational age specific and population specific reference
ranges for thyroid testing in pregnant women [90].
1.4 Infertility
1.4.1 Definition and Causes of Infertility
Fertility is ultimately assessed by a successful pregnancy. However, definitions of
infertility vary widely, impacting on estimated prevalence. The International
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Committee for Monitoring Assisted Reproductive Technology and the World Health
Organization (WHO) define (clinical) infertility as ‘a disease of the reproductive system
defined by the failure to achieve a clinical pregnancy after 12 months or more of
regular unprotected sexual intercourse’ [123]. For couples who are diagnosed as
infertile, further assessments are required to determine the underlying cause or
causes and recommend possible treatment options. Worldwide there are
approximately 72.4 million couples that experience fertility problems annually [124]. In
Australia, approximately one in six couples do not conceive in their first year of trying
[125].
There are many factors which contribute to infertility. Approximately one third of
cases of infertility are the result of female related factors, one third to male related
factors and one third are attributable to both partners or remain unexplained [126].
The most common causes of infertility are advanced maternal age [127], female
reproductive factors such as endometriosis, polycystic ovary syndrome and menstrual
cycle irregularities [126] and sperm production problems and blockage of sperm
transport in men [128]. Lifestyle factors in both genders are known to increase the risk
of infertility, some being drinking alcohol, smoking, higher body mass index (BMI) and
sexually transmitted diseases [129].
Humans are not particularly efficient at reproduction compared to other mammals.
The chance of getting pregnant (fecundity) is between 25 to 30% each month for the
first 3 to 6 months of trying [127]. The chance of conceiving dramatically decreases
once a woman reaches 31 years of age [130-132] due to a diminishing ovarian reserve,
which poses a problem for many couples who do not try to have children until they
reach their thirties.
1.4.2 Reproductive Ageing and Ovarian reserve
Reproductive ageing is associated with reduced fertility and the ovarian and hormonal
changes that occur in the lead up to menopause, when the permanent cessation of
menstruation resulting from the loss of ovarian follicular activity occurs [133].
Decreasing female fertility and ovarian ageing corresponds to a decrease in follicle
33
numbers and oocyte quality [134]. Depletion and resistance of the ovarian follicular
pool leads to reduced inhibin B production, reduced negative feedback at both
pituitary and hypothalamic levels, and elevated FSH and LH levels in the
perimenopause stage [135, 136].
Ovarian reserve is the term used to describe the remaining follicles in the ovary and
reflects the reproductive age of a woman [137]. A diminished ovarian reserve (DOR) is
strongly correlated with advanced maternal age [138]. Assessing ovarian reserve is a
useful tool in the management and treatment of patients undergoing assisted
reproduction. In the past, FSH has been the primary hormone used to assess ovarian
reserve and it is still routinely measured in the early follicular phase when investigating
infertile women. Women who have regular menstrual cycles but exhibit raised basal
FSH levels, will usually have a reduced ovarian reserve and are at a higher risk of
infertility [139, 140].
AMH has recently been shown to be an earlier indicator of ovarian reserve compared
to FSH, despite both hormones being associated with the changes that occur in
menopausal women [141]. AMH levels are declining soon after a woman’s menstrual
cycle becomes irregular which can occur in her mid to late thirties, whereas elevated
levels of FSH may not appear until after a woman reaches 45 years of age [135].
1.5 Assisted Reproductive Technology (ART)
1.5.1 Definition of ART and Procedures
Assisted reproductive technology (ART) is a term used to describe a group of
procedures involved in the in vitro (in glass) handling of human oocytes, sperm or
embryos for the purpose of achieving a pregnancy [123]. Approximately 4.1% of all
women who gave birth in Australia in 2010 received some form of ART treatment
[142].
The 2011 report from the Fertility Society of Australia (FSA), in collaboration with the
University of New South Wales (UNSW), categorise ART treatments according to
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whether a woman used her own oocytes or embryos in an autologous cycle, or
alternatively if oocytes/embryos are donated by another woman/couple and whether
the embryos are transferred soon after fertilisation (fresh cycle) or following
cryopreservation [1]. In 2011 there were 66,347 ART treatment cycles performed in
Australia and New Zealand, of which 95.1% of cycles were autologous and 33.7% of all
cycles used embryos thawed from cryopreservation [1].
Most people associate ART with the typical in vitro fertilisation (IVF) procedure which
encompasses controlled ovarian hyperstimulation, oocyte collection and fertilisation
with sperm in the laboratory, embryo maturation and then transfer of the fresh
embryo into the uterus [143]. A variation to this procedure is intracytoplasmic sperm
injection (ICSI), which involves a single sperm injected directly into the oocyte [144].
Male factor infertility is one of the primary causes of difficulties achieving a pregnancy
in couples [145] and ICSI has resulted in increased fertilisation and pregnancy rates in
cases where male sperm motility and quality were involved [144, 146].
Embryo cryopreservation plays a significant role in ART treatments. Frozen embryo
transfers (FET) are performed when embryos not transferred in the initial fresh
treatment cycle are cryopreserved, stored and once thawed can be transferred in
subsequent treatments. This provides more opportunities for patients to achieve a
pregnancy if their first attempt is unsuccessful, thereby improving cumulative
pregnancy rates [147, 148].
Other treatments which help infertile couples achieve a pregnancy include ovulation
induction in which the ovaries are stimulated by administering drugs such as
clomiphene or commercially produced FSH and LH injections in conjunction with timed
intercourse, or alternatively coupled with intrauterine insemination whereby semen is
prepared in the laboratory into a highly concentrated sample and then placed directly
into the female genital tract (intracervical insemination [ICI] or intrauterine
insemination [IUI]) [149].
Less common ART treatments include gamete intrafallopian transfer (GIFT), when
mature oocytes and sperm are placed directly into a woman’s fallopian tubes so that
35
fertilisation may take place in vivo (inside the body), zygote intrafallopian transfer
(ZIFT), when fertilisation takes place in vitro then transferred back to the fallopian
tubes and finally surrogacy arrangements, where a woman agrees to carry a child for
another person or couple with the intention that the child will be raised by the
intended person or couple [1].
1.5.2 Risks Associated with ART
Optimal evaluation of women and proper treatment are essential for a successful
outcome of ART and to minimise risks to the mother and unborn child. One risk
associated with ART is the increased risk of multiple gestation pregnancy, which in turn
can increase the health risks to both mothers and babies. These risks include
pregnancy and birthing complications, preterm delivery and low birthweight babies
[150, 151]. The risks in Australia have greatly minimised, since the percentage of single
embryo transfer cycles has increased from 63.7% in 2007 to 73.2% in 2011 [1].
Although there is a worldwide push to decrease the numbers of embryos transferred
after IVF, there still remains significant differences in practice between countries. The
policies regarding the number of embryos transferred in ART vary, therefore statistics
on multiple births are highly variable [152, 153].
Controlled Ovarian Stimulation (COS) is a process which is required for ART treatments
such as IVF and ICSI, where a high oocyte yield increases the chances of pregnancy by
having more embryos available for cryopreservation for use in subsequent cycles if the
first transfer is not successful [154] . COS involves priming the ovaries, usually by
administering FSH and then a trigger to induce final follicular maturation. A serious
complication or risk involved in COS is ovarian hyperstimulation syndrome (OHSS),
which affects approximately 1.4 % of all cycles [155]. In OHSS, the protein-rich fluid
shifts from the intravascular space (blood vessels) to the transcellular space in the
abdominal cavity as a result of increased vascular permeability following artificial
stimulation with human chorionic gonadotropin (hCG) or later in pregnancy when
there is a natural rise in hCG levels [156]. Symptoms of OHSS range from mild
abdominal distention due to enlarged ovaries alone or with an accompanying fluid
shift into the abdomen, to ascites, liver dysfunction, renal failure [157] and potential
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death as a result of haemoconcentration and reduced perfusion of vital organs such as
the brain [158].
There are many precautions that are taken to minimise the risks of OHSS, some of
which can include identifying high risk patients by measuring baseline AMH levels prior
to treatment to predict responsiveness to ovarian stimulation [159, 160], measuring
basal FSH, BMI, age and the number of follicles <11 mm [161], cycle cancellation[162],
withholding gonadotropin administration [163], cryopreservation of all embryos [164],
intravenous albumin administration [165] and the use of the dopamine agonist
cabergoline to suppress the pituitary [166, 167]. More recently, administering
gonadotropin-releasing hormone (GnRH) agonist as an oocyte trigger in GnRH
antagonist cycles instead of an hCG trigger has been shown to reduce the risk of OHSS,
but has also been associated with lowered live birth rates and ongoing pregnancy
rates, so should only be used in women with a higher risk of OHSS [168].
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2 Aims and Hypotheses
The proposed study uses automated immunoassay technology to measure
concentrations of circulating AMH, thyroid (TSH, fT3, fT4) and reproductive (E2, P4 and
hCG) hormones in women during early pregnancy (gestation week 4 to 7). The aims
were structured to test a number of null hypotheses as described below.
2.1 Aims
The specific aims of the study were to:
1. Evaluate the performance of the immunoassays used to measure these
hormones.
2. Compare the hormone concentrations in pregnancy to those seen before
the pregnancy was diagnosed.
3. Describe changes in these hormone concentrations from the time of a
positive pregnancy (two weeks after ovulation, or gestation week 4 using
the obstetric convention of time from the last menstrual period) to
gestation week 7.
4. Identify any association between these hormones in pregnancies that are
either viable or result in miscarriage.
2.2 Hypotheses
This study will test the following null hypotheses:
1. The immunoassays used to measure these hormones do not perform well in
the ranges of concentrations found in the study samples.
2. The reproductive hormones do not follow the classical patterns seen before
and during pregnancy.
3. AMH and thyroid hormone levels do not change following diagnosis of
pregnancy or during pregnancy.
4. There is no association between AMH or thyroid hormones in pregnancies
that are either viable or result in miscarriage.
5. There is no association between any of the reproductive and study
hormones during pregnancy.
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3 Materials and Methods
3.1 Ethics
Ethical approval to undertake this research project was given by the Joondalup Health
Campus Human Research Ethics Committee [JHC HREC, Reference 1414] and the Edith
Cowan University Human Research Ethics Committee [ECU HREC, Project 12077] as
shown in Appendices A and B respectively.
3.2 Study Participants
3.2.1 Selection and Recruitment
Women who attended Fertility North for fertility treatment were recruited on the
basis of a positive pregnancy blood test, namely if the serum hCG concentration was
>25 IU/mL. Women with a history of thyroid disease (ie pre-pregnancy baseline serum
TSH concentration outside the normal range 0.4-4.0 mU/L or outside the specific
pathology reference range for normal thyroid levels), as well as women taking thyroid
medication such as thyroxine were excluded from the study. Women who tested
positive for TPOAb were excluded prior to the analysis of thyroid hormone reference
ranges. All women were confirmed to be non-smokers, of an acceptable weight range
to commence ART in the clinic (BMI <35) and negative for HIV, Hepatitis B or C and
Syphilis, and positive for Rubella immunity.
The clinic’s electronic diary (Genie; Genie Solution Pty Ltd, Indooroopilly, Queensland)
was used to obtain each patient’s medical history (oral contraceptive use prior to
recruitment, fertility medications during their treatment cycle and starting body mass
index or BMI) and keep track of their scheduled phlebotomist appointments on any
given day.
Once a woman was identified as being pregnant, a note was put on her next
phlebotomist appointment on Genie, at which time the patient was presented with the
project information sheet (Appendix C) and invited to participate in the study. Once
the patient signed the consent form (Appendix D), her name was added to an Excel
spreadsheet of recruited patients.
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3.2.2 Treatment Cycles
All women recruited had regular pregnancy monitoring, however patients were
divided into four main groups based on the type of treatment they received leading up
to the time of conception. The first group of women were tracked during their natural
menstrual cycle for timed intercourse at the time of ovulation and were not prescribed
any medications. There were 15 women recruited in the ‘’Natural pregnancy cycle”
group.
The second group of women received high doses of stimulation medication, including
recombinant FSH, to produce multiple follicles for collecting and subsequent In-vitro
fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment. There were 25
women recruited in the “IVF/ICSI pregnancy cycle”.
In the third group of women, one or more embryos were implanted back into their
uterus via a Frozen Embryo Transfer (FET) if the first fresh embryo transfer from an IVF
or ICSI cycle was unsuccessful. FETs were performed in either natural or controlled
medicated cycles (used to better time the embryo transfer). There were 25 women
recruited in the “FET pregnancy cycle”.
Finally, the fourth group of women were administered low doses of stimulation drugs
to produce one follicle (OI or Ovulation Induction) for either timed natural intercourse
or artificial insemination (AI), where the semen was produced and prepared by the
laboratory before being administered into the uterus at the time of ovulation. There
were a total of 7 “AI pregnancy cycles” and 13 “OI pregnancy cycles”.
3.3 Hormone Assays
3.3.1 Sample Collection and Processing
All patient blood samples were taken at Fertility North by the clinic’s phlebotomists
between 7:00am and 9:00am according to the clinic’s Standard Operating Procedure
(SOP) “Venepuncture – The Collection of Blood Samples” (Appendix E) and processed
according to  “Patient Identification, Blood Sample Acceptance and Preparation for
Analysis” SOP (Appendix F).” Blood samples were centrifuged for 10 minutes at 3,700
rpm using a Beckman Coulter Allegra X-30 centrifuge.
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Bloods samples were collected twice weekly from gestation week 4 until fetal
heartbeat was seen by ultrasound (approximately gestation week 7). If a patient had a
chemical pregnancy or miscarried, blood samples were collected once weekly
thereafter, until the patient’s hCG <5 IU/mL. In addition to the post-pregnancy blood
samples that were collected, a pre-ovulatory or ovulatory sample (gestation week 2),
mid-luteal (gestation week 3) sample as well as a baseline (day 2) sample (where
available) were collected from each patient.
3.3.2 Reproductive Hormone Assays and Sample Storage
Patient serum was measured for the  standard reproductive hormones (E2, P4, and
hCG) using the Siemens Centaur XP Automated Analyser (Siemens, Bayswater 3053,
Victoria Australia) at Fertility North, adhering to the clinic’s SOP “Operation of the
Biochemistry Analyser (Siemens Advia Centaur XP)” (Appendix G) and “Assay Protocol
for Siemens Advia Centaur eE2, LH, P4, FSH and ThCG” (Appendix H). These hormones
formed part of the patient’s regular cycle tracking or pregnancy monitoring and were
requested by their doctor at Fertility North. All serum samples were stored in their
original collection tubes at 4°C for one week, then at -20°C until all the samples
obtained for each patient over their pregnancy monitoring were collected.
3.3.3 AMH Assays and Sample Storage
The blood samples from each patient/pregnancy were thawed at room temperature
and analysed together on the same day in one batch to minimise technical variability.
AMH concentrations were measured at PathWest Nedlands using the AMH GEN II
enzyme linked immunosorbent assay (ELISA) (Beckman Coulter) following the
manufacturers guide (Appendix N). A set of 7 calibrators for each AMH assay were
provided in the manufacturer’s kit to plot a calibration curve of absorbance versus
AMH concentration (Appendix O). Sample AMH concentrations were then able to be
calculated from this calibration curve.  Patient samples were then stored for a second
time at -20°C for further hormone testing at a later stage.
3.3.4 Thyroid Function and Oestradiol Assays
Patient samples were thawed at room temperature for a second time and analysed
together in batches to minimise technical variability. Each patient sample was assigned
a new barcode in numerical order so as to efficiently record, print and transfer the
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hormone results to an excel spreadsheet.  TSH, fT4, fT3 and E2 were measured in each
patient sample using the Siemens Centaur XP Automated Analyser (Siemens,
Bayswater,Victoria 3053, Australia) at Fertility North, adhering to the clinic’s SOP
“Operation of the Biochemistry Analyser (Siemens Advia Centaur XP)” (Appendix G)
and “Assay Protocol for Siemens Advia Centaur eE2, LH, P4, FSH and ThCG” (Appendix
H). One sample from each batch of patient pregnancy samples (gestation week 4 - 7)
was tested for thyroid peroxidase antibody (TPOAb) using the same protocols. Two
patient serum samples of known concentrations, one negative and one positive control
were used in the TPOAb assay.
3.4 Quality Assurance
3.4.1 AMH Stability
The Beckman Coulter AMH GEN II ELISA kit has specific recommendations by the
manufacturer for the pre-analytical preparation and storage of blood samples. Due to
the patient’s pre-pregnancy samples being collected retrospectively, they had already
been stored for one week at 4°C in their original collection tubes before being frozen
at -20°C (this is the clinic’s storage protocol). Therefore the effect upon AMH
concentration by storing patient serum in the refrigerator in the primary collection
tube for up to one week prior to assay, as opposed to the recommended maximum 48
hours then transferring to a secondary storage tube, was investigated.
Serum samples (n=20) were stored at 4°C for 7 days in either the original/primary 5ml
Vacutainer SST™ collection tube (Becton Dickinson, UK) or after transfer to a
secondary storage tube. 100µl aliquots were removed daily for 7 days from the
original serum sample and frozen at -20°C. All samples were stored for a further week
at -20°C prior to thawing at room temperature on the day of measurement. Results
were expressed as the mean (µ) ± standard error of mean (sem) or as a
proportion/percentage (%) of the original value. AMH concentration over time was
assessed using repeated measures ANOVA, and differences between tubes by paired
student t-test. Differences were considered significant if p<0.05. The concentration of
AMH did not differ significantly between the primary and secondary tubes (p=0.603)
and the relationship between the two is illustrated in Figure 1.
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Figure 1. Serum AMH concentrations (pmol/L) following short-term storage at -20˚C
in primary vs secondary tubes.
Serum AMH concentrations did not change significantly (p=0.811) (Table 1) over the 7
days in the collection tubes stored in the refrigerator (Table 2), decreasing by a mean
of only 2.8±2.6% (Table 3).
Table 1. Repeated measures ANOVA for AMH stability over 5 days.
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Table 2. Serum AMH (pmol/L) stability over 7 days at 4°C.
Sample
Day A B C D E µ ± sem
1 5.0 10.0 14.2 30.1 47.0 21.3 ± 7.7
2 6.8 11.0 15.9 28.5 38.4 20.2 ± 5.8
3 8.3 10.9 15.1 28.2 39.5 20.4 ± 5.9
4 7.8 10.6 15.9 29.5 40.5 20.9 ± 6.2
5 8.1 10.1 14.3 27.9 44.8 21.0 ± 6.9
6 7.9 10.2 14.3 26.2 38.0 19.3 ± 5.6
7 7.3 10.6 14.5 23.6 37.7 18.7 ± 5.5
Table 3. Serum AMH expressed as a percentage of the original sample tube.
Sample
Day A B C D E µ ± sem
1 100.0 100.0 100.0 100.0 100.0 100.0 ± 0.0
2 136.9 110.6 112.0 94.7 81.7 107.2 ± 9.3
3 121.2 98.5 94.5 98.8 102.8 103.2 ± 4.7
4 93.6 97.4 105.6 104.8 102.6 100.8 ± 2.3
5 104.3 95.3 89.6 94.4 110.5 98.8 ± 3.8
6 97.6 101.3 100.6 93.9 84.8 95.7 ± 3.0
7 91.9 103.6 101.3 90.1 99.2 97.2 ± 2.6
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3.4.2 AMH Assay Precision
The precision of the Beckman Coulter AMH Gen II ELISA kit was assessed using both
commercial quality control material and pooled patient serum. Intra-assay variation
was determined by analysing 20 replicates of 4 serum pools at know varied
concentrations (low, medium, high and very high). These pools were then run in each
of the 23 separate assays to indicate between-assay variability. Quality control
material (1 high and 1 low) provided by the kit manufacturer were also included in
each assay. Results were expressed as µ ± sem and a coefficient of variation (CV)
calculated as standard deviation (SD)*100/µ.
The mean AMH concentration (pmol/L) in 20 replicates of Pools A-D is shown in Table
4. A precision curve was plotted (Figure 2) to demonstrate the reproducibility of AMH
measurements at varying concentrations within one assay. The AMH Gen II assay
performed well at concentrations between 13.4pmol/L and 35.7pmol/L with CVs of
5.6% and 5.2% respectively. The average patient serum AMH concentration was
21.4±0.8pmol/L which fell within this range. Samples with low AMH levels
(<5.4pmol/L) had a higher CV of 10.5%.
Table 4. AMH (pmol/L) intra-assay variability of serum pools.
Pool µ ± sem CV (%)
A 5.4 ± 0.02 10.5
B 13.4 ± 0.02 5.6
C 35.7 ± 0.06 5.2
D 94.9 ± 0.27 9.0
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Figure 2. Beckman Coulter AMH Gen II intra-assay precision profile.
The variation in AMH measurements between assays was evident, both in pooled
serum (Table 5) and commercially prepared internal controls (Table 6). A precision
curve of the variability between assays is shown in Figure 3. Serum Pool A had the
highest variability between assays, with a CV of 15.9% at an AMH level of
4.9±0.2pmol/L. The manufacturer’s internal control 2 had the best reproducibility with
a CV of 5.1% at mean AMH concentration of 57.7±1.1pmol/L, compared to Pool C that
had the lowest CV of all the Pools (8.0%) at mean AMH concentration of
30.5±0.5pmol/L. The effect of inter-assay variability was therefore eliminated for each
woman by analyzing all samples for one cycle in one assay.
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Table 5. AMH (pmol/L) inter-assay variability of serum pools.
Pool µ ± sem CV (%)
A 4.9 ± 0.2 15.9
B 11.7 ± 0.3 11.1
C 30.5 ± 0.5 8.0
D 92.2 ± 2.1 11.2
Table 6. Inter-assay variability of AMH Gen II internal controls (pmol/L).
Control µ ± sem CV (%)
1 19.4 ± 1.8 8.5
2 57.7 ± 1.1 5.1
Figure 3. Beckman Coulter AMH Gen II inter-assay precision profile.
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3.4.3 Thyroid Assay Precision
The precision of the Siemen’s thyroid hormone reagents (fT3, fT4 and TSH) were
analysed using both commercial QC material (Bio-rad Lyphochek Immunoassay Plus
Control 1, 2 and 3, Irvine, CA) and pooled patient serum. Intra-assay variation was
determined for each thyroid hormone by analysing 20 replicates of 3 serum pools at
concentrations representative of the mean levels found in the patient sample
population. Two of these serum pools were then run in each of the 12 separate assays
to indicate between-assay variability and reflect the nature of the patient samples
being measured. Quality control material (three levels) provided by the manufacturer
were also included in each assay. Results were expressed as µ ± sem and CV. Analysis
of three different pooled sera samples at three different concentrations revealed
excellent reproducibility for the fT3, fT4 and TSH assays (Tables 7 - 9 and Figures 4 - 6),
with the average CV of each assay being <5.0%. The concentrations of each pooled
sample were close to the average levels of thyroid hormones typically found in each
patient.
Table 7. Within-assay performance of fT3 (pmol/L) using pooled sera.
µ ± sem CV (%)
fT3 A 4.59 ± 0.03 3.16
fT3 B 4.94 ± 0.02 2.12
fT3 5.04 ± 0.03 2.39
Figure 4. Siemens fT3 intra-assay precision profile.
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Table 8. Within-assay performance of fT4 (pmol/L) using pooled sera.
µ ± sem CV (%)
fT4 A 15.04 ± 0.11 3.23
fT4 16.26 ± 0.17 4.75
fT4 B 17.46 ± 0.20 5.23
Figure 5. Siemens fT4 intra-assay precision profile.
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Table 9. Within-assay performance of TSH (mU/L) using pooled sera.
µ ± sem CV (%)
TSH A 1.77 ± 0.01 2.75
TSH 1.96 ± 0.01 1.60
TSH B 2.64 ± 0.02 2.60
Figure 6. Siemens TSH intra-assay precision profile.
Two external controls (derived from pooled patient sera) and three internal quality
controls (provided by the manufacturer) were run in each of 12 different assays to
establish between-assay variation for fT3, fT4 and TSH as shown in Tables 10 - 12 and
Figures 7 - 9. The effect of inter-assay variability for all thyroid hormones was
eliminated for each woman by analyzing all samples for one cycle in one assay.
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Table 10. Inter-assay variability of fT3 (pmol/L).
µ ± sem CV (%)
fT3 QC1 3.72 ± 0.03 2.87
fT3 A 4.62 ± 0.03 2.53
fT3 B 4.99 ± 0.04 2.77
fT3 QC2 10.33 ± 0.08 2.56
fT3 QC3 16.80 ± 0.19 3.90
Figure 7. Siemens fT3 inter-assay variability.
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Table 11. Inter-assay variability of fT4 (pmol/L).
µ ± sem CV (%)
fT4 QC1 9.80 ± 0.19 8.91
fT4 A 16.41 ± 0.29 6.06
fT4 B 17.99 ± 0.39 7.48
fT4 QC2 24.43 ± 0.29 4.06
fT4 QC3 47.88 ± 0.68 4.93
Figure 8. Siemens fT4 inter-assay variability.
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Table 12. Inter-assay variability of TSH (mU/L).
µ ± sem CV (%)
TSH QC1 0.35 ± 0.00 3.41
TSH A 1.61 ± 0.05 9.94
TSH B 2.44 ± 0.05 6.81
TSH QC2 4.86 ± 0.05 3.61
TSH QC3 32.05 ± 0.35 3.80
Figure 9. Siemens TSH inter-assay variability.
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3.4.4 Reproductive Hormone Quality Controls
To monitor hormone assay performance and maintain a high level of precision in the
laboratory, Internal Quality Controls (Bio-rad Lyphochek Immunoassay Plus Control 1,
2 and 3, Irvine, CA) were used in every run. Fertility North is also enrolled in two
External Quality Assurance Schemes for the measurement of five reproductive
hormones, including E2, P4 and hCG (Appendix L). A patient sample repeat from a
previous assay was also measured for all hormones on each run.
3.4.5 Measurement Uncertainty
There is a degree of variability between the reproductive hormone concentrations
(Oestradiol, P4 and hCG) measured on different occasions (refer to Appendix M),
therefore care must be taken when interpreting such results. Because E2 was not
routinely measured, it was measured in all patient samples in batches to minimise
technical variability. The P4 and hCG levels were measured routinely on the day of
each sample collection and recorded.
3.4.6 Reproductive Hormone Linearity
The reproductive hormone assays (oestradiol, progesterone and hCG) were further
validated by demonstrating the linearity of hormone measurements in selected
samples because the concentrations often extended beyond the range of the standard
curve. Serial dilutions (1:1, 1:2, 1:4, 1:8, 1:16, 1:32) were performed on the
reproductive hormones E2, P4 and hCG in patient blood serum samples with known
high concentrations. One patient sample from each of the four different cycle types
(Natural, OI, IVF/ICSI and FET) that had been identified as having a positive pregnancy
test were used to measure each reproductive hormone. Samples were diluted
manually using a transfer pipette and adding the required amount of each hormone’s
specific diluent (Appendix J).
Samples were measured on the Siemens Centaur XP Automated Analyser, adhering to
the clinic’s SOP “Operation of the Biochemistry Analyser (Siemens Advia Centaur XP)”
(Appendix G) and “Assay Protocol for Siemens Advia Centaur eE2, LH, P4, FSH and
ThCG” (Appendix H). The observed concentrations of each test were plotted against
the expected concentrations to determine the gradient, correlation and intercept
values (Tables 13 - 15 and Figures 10 - 12). The sample used to plot the linearity graph
for each hormone is marked with an asterix. In essence, all three assays showed good
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linearity with correlations ≥0.997, and gradients close to 1.000. E2 and P4 had
intercepts close to the origin and hCG appeared to have the largest shift from the
intercept, but this was acceptable given the high values measured.
Table 13. Mean E2 difference (%) following serial dilutions in difference treatment
cycles.
Patient Cycle
Parameter IVF/ICSI* FET Natural
gradient 1.012 1.020 1.018
correlation 0.999 0.999 0.997
intercept -86.766 -98.572 -88.831
Figure 10. Serial Dilution of E2 in an IVF/ICSI patient serum sample.
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Table 14. Mean P4 difference (%) following serial dilutions in difference patient
cycles.
Patient Cycle
Parameter IVF/ICSI* FET Natural
gradient 0.999 1.016 1.015
correlation 0.999 0.999 0.997
intercept -3.638 -0.825 1.673
Figure 11. Serial Dilution of P4 in an IVF/ICSI patient serum sample.
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Table 15. Mean hCG difference (%) following serial dilutions in difference patient
cycles.
Patient Cycle
Parameter IVF/ICSI FET Natural
gradient 1.003 1.018* 1.013
correlation 0.998 0.999 0.999
intercept 55.104 -1701.378 -469.458
Figure 12. Serial Dilution of hCG in an IVF/ICSI patient serum sample.
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3.4.7 Reproductive Reagents and Calibrations
Reagents and calibrators were closely monitored and recorded to keep track of lot
numbers to ensure they are all used within their expiry dates (Appendix I). All the
primary hormone reagents (E2, P4, hCG, TSH, fT3, fT4 and TPOAb) were calibrated
prior to use, with their specific calibrator (Appendix J). Lyophilized calibrators were
prepared by adding the required amount of deionized water (Ibis Technology, Mt
Hawthorn) and all consumables stored at 2‐8˚C in the fridge or on-board the Siemens
Centaur XP for the recommended duration as recommended by the manufacturer
(Appendix J).
3.5 Data Collection and Statistical Analysis
3.5.1 Recording and Storage of Hormone Results
All patient hormones that formed part of their routine fertility treatment (P4 and hCG)
were automatically recorded on the Centaur XP, then printed and recorded in the
clinic’s main database program ‘PRAGMA’ (ARTEMIS, 1991) adhering to Fertility
North’s SOP “Recording Blood Test Results that are Collected and Analysed Internally”
(Appendix K).
Once patients had completed their pregnancy hormone monitoring, these results were
collected retrospectively and transferred to an Excel spreadsheet located within the
clinic’s network, which was password protected. Patient’s AMH, E2, TSH, fT3 and fT4
hormone results were printed and entered manually into an excel spreadsheet also
saved within the clinic’s network.
Names were initially associated with these results so as to search for their medical
history and treatment information within their records at Fertility North. Patient’s
names were de-identified upon data analysis and will not be released upon publication
of any results.
3.5.2 Statistical Analysis of Hormones
De-identified information was analysed under the guidance of a suitably qualified
statistician at Edith Cowan University. Quantification of within- and between-assay
variability for all hormones was determined by calculating the mean (µ), standard error
of mean (sem) and coefficient of variation (CV) using Microsoft Excel. The age of viable
and non-viable women was expressed in mean ± sem and p-value calculated using 2-
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tailed t-test (two sample, unequal variance). Analysis of the relationships between
hormones and other variables (gestation week, treatment or cycle type, patient age,
patient BMI, FSH dose, viability of pregnancies and fetal gender) were performed using
IBM SPSS Statistics Version 22.
The relationships between E2, P4, hCG, AMH, TSH, fT3 and fT4, gestation week, age
and BMI during pregnancy were analysed using bivariate correlations (2-tailed,
Spearman) to determine the correlation coefficient (r) and p-value (significance). The
relationship between FSH dosage (ovarian stimulation) and AMH levels at gestation
week 4 were also investigated in this way.
The relationships between each of the hormones during pregnancy were further
investigated by partial correlations, controlling for cycle type and cycle and week
combined. Patterns between hormones were visualized by generating scatterplots for
the partial correlations between AMH or Thyroid hormones and other hormones that
showed a significant correlation.
General linear models - repeated measures ANOVA were used to measure the
relationships between E2, P4, hCG, AMH, TSH, fT3 and fT4 and gestation week. Cycle
type and pregnancy outcome (viability) were investigated as between-subject factors
for AMH and thyroid hormones. Non-pregnant or baseline (gestation week 0) AMH
and thyroid levels were compared to each gestation week before and during
pregnancy. Hormone values from gestation week 7 were excluded from all ANOVA
analyses due to the drop in patient numbers affecting the power of calculations.
Tests for normality were significant (ie not normally distributed) for all hormones
besides fT3 and fT4; therefore the logarithm of variables were also analysed and
Spearman’s rank of p-value was reported as significant if p=<0.05. Results from ANOVA
calculations were reported as F(df1/H, df2/error) (p-value) and Partial Eta (power). P-values
were calculated using Wilks' Lambda, or Pillai's Trace if Levene's Test of Equality of
Error Variances or Box's Test of Equality of Covariance Matrices were not satisfied
(p=>0.05).
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Reference ranges were calculated for thyroid hormone concentrations in early
pregnancy by determining the 2.5th and 97.5th percentiles, minimum (min) and
maximum (max), median and mean ± sem concentrations at each gestation time point.
TSH concentrations were log transformed to define ranges within a normal
distribution. Nonviable pregnancies and women who tested positive for TPOAb were
excluded from the analysis.
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4 Reproductive Hormone Results
4.1 Oestradiol
Table 16 shows the mean concentration and confidence intervals of E2 during early
pregnancy. E2 increases significantly with advancing gestational age (p=0.000) (Table
17).
Table 16. E2 levels (mean ± sem) and confidence intervals for viable pregnancies
from gestation weeks 4 to 6.5 (n=55).
Gestation
Week Mean (pmol/L) Sem
95% CI
Lower Upper
4 1205.9 154.1 896.9 1515.0
4.5 1608.7 227.3 1152.9 2064.5
5 1979.3 276.9 1424.2 2534.4
5.5 2183.1 311.3 1558.9 2807.3
6 2338.3 332.1 1672.5 3004.0
6.5 2436.4 299.5 1835.9 3036.8
Table 17. Repeated measures ANOVA for E2 gestation weeks 4 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 9.018 5 50 0.000 0.474 45.088 1.000
64
4.2 Progesterone
Table 18 shows the concentration and reference intervals of P4 during early
pregnancy. Progesterone levels remain constant (p=0.211) (Table 19) between
gestation weeks 4 to 6.5, ranging from the highest level of 199.7 ± 27.5 nmol/L at
gestation week 4 to the lowest level of 177.0 ± 18.5 at gestation week 6.5.
Table 18. P4 levels (mean ± sem) and confidence intervals for viable pregnancies
from gestation weeks 4 to 6.5 (n=57).
Gestation
Week Mean (nmol/L) Sem
95% CI
Lower Upper
4 199.7 27.5 144.6 254.7
4.5 198.6 23.9 150.6 246.6
5 194.1 21.2 151.6 236.6
5.5 187.2 19.7 147.7 226.7
6 181.1 18.9 143.3 218.9
6.5 177.0 18.5 140.0 214.1
Table 19. Repeated measures ANOVA for P4 gestation weeks 4 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 1.485 5 52 0.211 0.125 7.423 0.480
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4.3 Human Chorionic Gonadotropin
Table 20 shows the changes in hCG concentration during early pregnancy. Levels of
hCG increased significantly with increasing gestational age (p=0.000) (Table 21). hCG
levels increased by a mean factor of 3.2 every 3 days, from the time of positive
pregnancy test at gestation week 4 (251.9 ± 30.1 mU/ml) to 53844.4 ± 3525.2 at
gestation week 6.5.
Table 20. hCG levels (mean ± sem) and confidence intervals for viable pregnancies
from gestation weeks 4 to 6.5 (n=57).
Gestation
Week Mean (mU/mL) Sem
95% CI
Lower Upper
4 251.9 30.1 191.6 312.2
4.5 1384.1 182.2 1019.2 1749.0
5 5187.5 565.4 4054.8 6320.2
5.5 13852.5 1167.7 11513.3 16191.6
6 29686.4 2183.5 25312.4 34060.4
6.5 53844.4 3525.2 46782.6 60906.2
Table 21. Repeated measures ANOVA for hCG gestation weeks 4 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 48.093 5 52 0.000 0.822 240.466 1.000
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5 AMH Results
5.1 AMH Levels in the Menstrual Cycle and Early Pregnancy
The AMH concentrations (mean ± sem) for each cycle type at baseline (day two of the
menstrual cycle), ovulation and mid-luteal are displayed in Table 22. Only the women
with measurements taken at all three time points were included in the analysis. The
percentage AMH change (%) for each woman at the time of ovulation and mid-luteal
(calculated as the percentage change from their baseline AMH measurement) is shown
in Figures 13 - 16 for all cycle types, except IVF/ICSI cycles due to the very low
concentrations. The AMH levels at baseline were strongly correlated with both
ovulation and mid-luteal time points (Table 23).
Table 22. AMH concentrations (mean ± sem) for each cycle type at various stages of
the menstrual cycle.
Baseline Ovulation Mid-luteal
IVF/ICSI (n=2) 2.3 ± 0.8 2.4 ± 1.0 2.6 ± 0.4
Natural (n=14) 18.0 ± 3.8 21.3 ± 5.7 21.4 ± 5.4
FET (n=18) 23.3 ± 4.4 26.7 ± 5.6 18.9 ± 4.0
AIH (n=3) 25.8 ± 5.9 41.2 ± 9.0 30.6 ± 8.1
OI (n=6) 60.5 ± 17.2 59.0 ± 16.6 50.2 ± 14.4
Table 23. Correlation (r) for AMH levels at ovulation or mid-luteal compared to
baseline levels for each cycle type.
Baseline vs
Ovulation
Baseline vs
Mid-Luteal
AIH (n=3) 0.88 0.91
FET (n=18) 0.97 0.95
OI (n=6) 0.87 0.95
Natural (n=14) 0.95 0.92
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Figure 13. Percentage AMH change (%) from baseline for women in natural cycles
(n=14).
Figure 14. Percentage AMH change (%) from baseline for women in FET cycles (n=18).
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Figure 15. Percentage AMH change (%) from baseline for women in AIH cycles (n=3).
Figure 16. Percentage AMH change (%) from baseline for women in OI cycles (n=6).
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Due to the small number of women with bloods taken at all three time points
(baseline, ovulation and mid-luteal) in some cycle groups, power to detect statistical
significance between time points within these groups was low, therefore p-values
were not included in this analysis. However, when looking at all viable pregnancies
(regardless of cycle type), there were significant differences in AMH levels observed at
various time points before and during pregnancy (p=0.005) (Table 24). Table 25 shows
the mean AMH levels for all cycle types before and during pregnancy (gestation weeks
0 to 6.5). The largest difference in AMH levels existed between time of ovulation (30.7
± 5.5 pmol/L) and gestation week 6 (18.7 ± 3.1 pmol/L) with a mean difference of
12.07pmol/L.
Table 24. Repeated measures ANOVA for AMH gestation weeks 0 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 3.912 8 23 0.005 0.576 31.297 0.950
Table 25. AMH levels (mean ± sem) and confidence intervals for gestation weeks 0 to
6.5.
Week
Mean
(pmol/L) Sem
95% CI
Lower Upper
0 25.8 4.3 17.0 34.6
2 30.7 a, b 5.5 19.6 41.9
3 24.6 c 4.2 16.0 33.1
4 21.6 3.4 14.7 28.5
4.5 21.1 3.2 14.5 27.7
5 19.6 2.8 13.8 25.4
5.5 20.4 a 3.2 13.8 27.1
6 18.7 b, c 3.1 12.3 25.1
6.5 20.3 3.5 13.2 27.4
Note – concentrations with same superscript are significantly different (p<0.05)
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Although the mean AMH levels peaked at time of ovulation (gestation week 2), it is
important to note that this was not the same for each woman. Only 53.5% of patients
(with blood samples taken at gestation weeks 0, 2 and 3) had maximum AMH levels at
gestation week 2, with 32.6% having their highest AMH level measured at baseline
(gestation week 0) and 13.9% at mid-luteal (gestation week 3). The maximum
(highlighted red), middle (yellow) and lowest (green) AMH level measured during the
menstrual cycle for each woman is shown in Table 26.
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Table 26. AMH levels (pmol/L) for each woman during the menstrual cycle.
Cycle Baseline Ovulation Mid-luteal
AIH 17.18 23.79 15.27
AIH 23.08 45.90 33.89
AIH 37.04 53.98 42.57
FET 3.94 3.66 2.78
FET 7.96 6.34 7.36
FET 12.11 7.31 7.00
FET 18.68 18.49 16.09
FET 10.22 19.83 8.51
FET 15.43 20.91 17.81
FET 28.12 23.08 18.09
FET 15.00 25.10 12.34
FET 23.71 27.18 19.84
FET 27.94 29.25 26.90
FET 42.47 37.49 24.31
FET 40.10 44.59 25.63
FET 31.87 45.35 35.70
FET 2.51 0.63 0.69
FET 6.80 8.25 5.07
FET 79.03 101.94 74.25
FET 13.28 14.02 10.72
FET 39.63 46.60 26.31
ICSI 3.08 3.31 2.93
IVF 1.56 1.39 2.20
OI 28.39 37.63 39.31
OI 112.48 71.51 89.30
OI 71.03 79.24 71.11
OI 106.25 124.37 80.75
OI 25.15 19.35 12.08
OI 19.83 21.89 8.53
TRACK 4.01 3.26 6.73
TRACK 3.26 6.74 4.28
TRACK 9.87 8.33 9.07
TRACK 10.17 10.00 9.31
TRACK 11.62 13.24 17.96
TRACK 7.40 13.76 12.32
TRACK 11.07 14.13 9.56
TRACK 17.71 15.61 21.98
TRACK 20.06 17.27 19.19
TRACK 20.89 20.01 17.96
TRACK 29.27 23.22 15.75
TRACK 28.29 36.56 47.65
TRACK 57.81 88.38 81.00
TRACK 20.43 27.05 26.21
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5.2 AMH Levels in Early Pregnancy
5.2.1 Overall Changes Over Time
The mean AMH concentrations (pmol/L) when measured for all patients at each time
point (gestation weeks 4-7) did not show any significant differences (r=-0.012,
p=0.784), with the lowest AMH level of 18.1pmol/L calculated at gestation week 7,
compared to the highest AMH level of 20.5pmol/L calculated at gestation week 4
(Figure 17). The number of patients with serum available decreased at each gestation
week due to some patients having earlier ultrasounds than routinely performed at
week 7, after which time no further blood samples were required when a positive fetal
heart was detected.
Figure 17. Serum AMH concentrations (mean ± sem) from gestation week 4 to week
of fetal heartbeat detected by ultrasound. Number of patient samples available for
analysis at each gestation week is shown within each column.
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5.2.2 AMH Levels between Weeks
AMH levels were not significantly different between gestation weeks 4 to 6.5 for all
viable pregnancies (p=0.278) (Table 27). AMH levels during pregnancy were also
analyzed between gestation weeks 4 to 6.5 for each cycle type. There were no
significant differences observed between gestation weeks 4 and 6.5 for IVF/ICSI
(p=0.404), FET (p=0.677) or OI/AIH (p=0.820) cycles (Tables 28 - 30). However in
natural cycles, there were significant difference observed (p=0.028) (Table 31), with
AMH levels decreasing from 24.7pmol/L at gestation week 4 to 18.7 pmol/L at
gestation week 6 (Table 32).
Table 27. Repeated measures ANOVA for AMH gestation weeks 4 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 1.302 5 50 0.278 0.115 6.512 0.422
Table 28. Repeated measures ANOVA for AMH levels gestation weeks 4 to 6.5 in
IVF/ICSI cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 1.093 5 15 0.404 0.267 5.465 0.284
Table 29. Repeated measures ANOVA for AMH levels gestation weeks 4 to 6.5 in FET
cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 0.634 5 17 0.677 0.157 3.170 0.179
Table 30. Repeated measures ANOVA for AMH levels gestation weeks 4 to 6.5 in
OI/AIH cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 0.423 5 7 0.820 0.232 2.115 0.105
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Table 31. Repeated measures ANOVA for AMH gestation weeks 4 to 6.5 in Natural
cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 5.031 5 7 0.028 0.782 25.154 0.770
Table 32. AMH concentrations (mean ± sem) and confidence intervals for natural
cycle patients in early pregnancy (n=12).
Gestation
Week Mean (pmol/L) Sem
95% CI
Lower Upper
4 24.7 a 5.0 13.6 35.8
4.5 22.5 b 4.5 12.7 32.4
5 21.1 4.5 11.2 31.0
5.5 21.6 5.2 10.1 33.0
6 18.7 a, b 4.5 8.7 28.6
6.5 20.8 5.9 7.7 33.9
Note – concentrations with same superscript are significantly different (p<0.05)
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5.2.3 Between Patient Variability on Day of Positive Pregnancy Test
When comparing AMH levels between patients at any one given time point, there
were substantial variations. For example, the AMH concentration for each woman at
the beginning of the pregnancy (week 4 or the time of positive pregnancy test) ranged
from 1.1pmol/L to 69.4pmol/L (Figure 18), and reflects the wide range of baseline
values and ovarian reserves.
Figure 18. Inter-woman serum AMH concentrations (pmol/L) at gestation week 4 for
different cycle types.
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5.2.4 Proportional AMH Change
Due to the high variation in AMH concentrations between each patient, levels were
then expressed as the mean percentage change over time (from gestation week 4 to
week of fetal heart detected by ultrasound), to more accurately determine individual
AMH changes that occurred. The AMH concentrations during each patient’s pregnancy
did not remain stable, but consistently changed and either increased or decreased
(Figure 19). The largest increase in AMH levels during early pregnancy was seen in an
OI patient where her AMH level increased by a mean of 114.1% in the small time of 2.5
weeks, increasing from 40.6pmol/L at gestation week 4 to 111.2pmol/L in gestation
week 6.5. In contrast, a woman who fell pregnant in a natural cycle had AMH levels
decrease by a mean of 72.4%, dropping from 6.6pmol/L at gestation week 4 to
0.6pmol/L at gestation week 6.5.
When dividing the patients into two sub groups that had either a mean increase or
decrease in AMH (AMH trend), there was a statistically significant difference between
these groups (p=0.000) (Table 33). Mean AMH variance between increasing or
decreasing trend was almost seven times larger than the variance within the weeks,
with a very strong effect size (Power = 0.996). The pattern between pregnancies that
increased in AMH compared to those that decreased was discernible across gestation
weeks 4 to 6.5 (Table 34 and Figure 20), where the estimated means follow opposite
lines, crossing over between gestation weeks 4 and 4.5 and the dispersion between
the two groups increased as the pregnancy progressed.
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Figure 19. Percentage AMH change (%) of viable pregnancies from gestational week 4 to fetal heart detected by ultrasound (n=70).
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Table 33. Repeated measures ANOVA for AMH gestation weeks 4 to 6.5 with AMH
trend as between subject factor.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
trend 6.712 5 50 0.000 0.406 6.512 0.996
Table 34. AMH levels (mean ± sem) and confidence intervals in patients that
increased compared to those that decreased.
AMH Trend Week Mean Sem
95% CI
Lower Upper
Decrease
4 21.9 a, b, c 2.9 16.1 27.8
4.5 19.5 3.0 13.4 25.6
5 17.8 a 2.9 12.0 23.7
5.5 17.4 b 3.0 11.4 23.4
6 17.1 c 3.2 10.8 23.4
6.5 17.1 c 3.5 10.0 24.2
Increase
4 18.7 a, b, c 3.7 11.2 26.2
4.5 22.0 3.9 14.2 29.7
5 22.7 3.7 15.2 30.1
5.5 23.2 a 3.8 15.6 30.8
6 23.3 b 4.0 15.2 31.3
6.5 25.6 c 4.5 16.5 34.6
Note – concentrations with same superscript are significantly different (p<0.05)
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Figure 20. Mean AMH in patients that increased compared to those that decreased.
5.2.5 AMH Levels between Treatment Modality
AMH concentrations were compared between each cycle type at gestation week 4
(time of positive pregnancy test) and baseline (gestation week 0) for those women
who had both bloods collected (Table 35). OI patients exhibited the highest AMH levels
at the time of positive pregnancy test (32.4± 5.6pmol/L), compared to IVF/ICSI patients
who had the lowest AMH levels (3.2pmol/L) at the same time point, probably
reflecting the allocation of treatment modality according to ovarian reserve.
Table 35. AMH concentration (mean ± sem) and confidence intervals for each cycle
type at gestation week 0 and 4.
Cycle Week Mean(pmol/L) Sem
95% CI
Lower Upper
IVF/ICSI
(n=2)
0 2.3 16.5 -31.0 35.6
4 3.2 12.5 -22.1 28.4
FET
(n=19)
0 24.1 5.3 13.3 34.9
4 17.0 4.1 8.9 25.2
OI/AIH
(n=10)
0 44.2 7.4 29.3 59.1
4 32.4 5.6 21.2 43.7
NATURAL
(n=14)
0 18.0 6.2 5.4 30.6
4 20.0 4.7 10.5 29.6
There was a significant difference in AMH levels between cycle types (p=0.009) (Table
36). Pairwise comparisons revealed significant differences between IVF/ICSI and all
other cycle groups (FET, OI/AIH and Natural) (Table 37). Games-Howell was the post
hoc test used as variances were not equal between groups.
Table 36. Repeated measures ANOVA for AMH gestation weeks 0 vs 4 with cycle type
as between subject factor.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
cycle 4.377 3 41 0.009 0.243 13.130 0.838
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Table 37. AMH levels (mean ± sem) and confidence intervals between cycle types.
Mean
difference Sem Sig.
95% CI
Lower Upper
IVF/ICSI
FET -17.8 3.6 0.001 -28.1 -7.6
OI/AIH -35.6 10.1 0.027 -67.0 -4.1
NATURAL -16.3 4.0 0.006 -28.0 -4.5
FET
IVF/ICSI 17.8 3.6 0.001 7.6 28.1
OI/AIH -17.8 10.7 0.387 -49.8 14.3
NATURAL 1.6 5.4 0.992 -13.1 16.2
OI/AIH
IVF/ICSI 35.6 10.1 0.027 4.1 67.0
FET 17.8 10.7 0.387 -14.3 49.8
NATURAL 19.3 10.8 0.328 -12.9 51.6
NATURAL
IVF/ICSI 16.3 4.0 0.006 4.5 28.0
FET -1.6 5.4 0.992 -16.2 13.1
OI/AIH -19.3 10.8 0.328 -51.6 12.9
AMH levels decreased significantly from gestation week 0 to 4 in OI/AIH and FET
patients (Table 38 and Table 39 respectively), however, there were no significant
differences between gestation weeks 0 and 4 for patients in IVF/ICSI or Natural cycles
(p=0.497 and p=0.251 respectively) (Tables 40 and 41) but there were only two
IVF/ICSI patients with AMH levels tested at gestation week 0, so this analysis did not
accurately reflect the patients in this cycle group as a whole.
Table 38. Repeated measures ANOVA for AMH levels at gestation weeks 0 vs 4 for
OI/AIH cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 5.038 1 9 0.050 0.359 5.038 0.517
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Table 39. Repeated measures ANOVA for AMH levels at gestation weeks 0 vs 4 for
FET cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 16.038 1 18 0.001 0.471 16.038 0.966
Table 40. Repeated measures ANOVA for AMH levels at gestation weeks 0 vs 4 for
IVF/ICSI cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 1.017 1 1 0.497 0.504 1.017 0.073
Table 41. Repeated measures ANOVA for AMH levels at gestation weeks 0 vs 4 for
Natural cycles.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 1.443 1 13 0.251 0.100 1.443 0.200
5.2.6 AMH Levels in Viable vs Nonviable Pregnancies
There were a total of 85 patients recruited in this study, of which 81.2% (n=69) were
single viable pregnancies and 17.6% (n=15) were nonviable pregnancies (consisting of
3 chemical pregnancies, 11 miscarriages and 1 blighted ovum) and there was 1 twin
viable pregnancy (1.2%). The cycle groups that had the highest nonviable pregnancy
rate of 24.0% were the FETs and IVF/ICSI, compared to the AIH group that had no
failed pregnancies (Table 42). There was 1 natural (6.7%) and 2 OI (15.4%) patient
cycles that resulted in miscarriage or chemical pregnancies (Table 38). The AMH
concentrations of all nonviable pregnancies are shown in Table 43. There was no
significant difference in age between women that had viable (37.0 ± 0.5 years) or
nonviable pregnancies (35 ± 1.3 years) (p=0.214).
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Table 42. Number of nonviable pregnancies in each cycle type.
NATURAL IVF/ICSI FET AIH OI
Total 15 25 25 7 13
Nonviable 1 6 6 0 2
Percentage (%) 6.7 24.0 24.0 0.0 15.4
Table 43. AMH levels (mean ± sem) and confidence intervals in nonviable
pregnancies.
Week Mean (pmol/L) Sem
95% CI
Lower Upper
4 22.6 a 5.3 12.0 33.1
4.5 25.2 5.6 14.0 36.4
5 23.9 5.5 12.9 34.8
5.5 23.2 5.5 12.2 34.2
6 24.4 6.1 12.3 36.6
6.5 28.1 a 6.7 14.8 41.5
Note – concentrations with same superscript are significantly different (p<0.05)
There were clear differences observed in the patterns of AMH change between viable
and nonviable pregnancies. Patients that had nonviable pregnancies had inconsistent
levels of AMH from time of positive pregnancy test (gestation week 4) to their final
blood test (when hCG ≤ 5IU/mL). AMH levels in nonviable pregnancies were unstable,
with rapid or sporadic increases and decreases (Figure 21). In contrast, AMH levels in
viable pregnancies followed either an increasing or decreasing trend from gestation
week 4 to detection of a fetal heartbeat, irrespective of their treatment cycle (Figures
22 - 25). When viability was analysed as an independent factor/between subjects
effect, it was shown that the mean AMH concentration was not significant between
weeks 4 to 6.5 (F=0.540, p=0.465, Partial Eta = 0.008, Power=0.112). However, the
power to detect significant change was limited by the smaller number of nonviable
pregnancies (n=15) compared to viable pregnancies (n=70).
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Figure 21. Percentage AMH change in nonviable pregnancy cycles.
Figure 22. Percentage AMH change in Natural viable pregnancy cycles.
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Figure 23. Percentage AMH change in viable pregnancies following IVF/ICSI cycles.
Figure 24. Percentage AMH change in viable pregnancies following FET cycles.
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Figure 25. Percentage AMH change in viable pregnancies following OI/AIH cycles.
-60.0
-40.0
-20.0
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
180.0
4 4.5 5 5.5 6 6.5P
erc
en
tag
e (
%)
 AM
H c
ha
ng
e
fro
m 
ges
tat
ion
 we
ek
 4
Gestation Week
88
5.3 Relationship between AMH and other Factors
5.3.1 AMH and Age
The average age of all women (n=85) in this study was 35.4 ± 0.5years. Baseline (day
two of the menstrual cycle) blood samples were collected for 45 women and assessed
for AMH concentration. Women were divided into four age groups at the time of their
first blood collection (26-30 years, 31-35 years, 36-39 years and 40 years and older)
and there was a significant difference in AMH levels between all age groups (p=0.000).
The mean AMH concentration determined for each group is shown in Table 44. It was
shown that there was a significant negative correlation between baseline AMH and
age (r=-0.507, p=0.000) (Figure 26), despite the wide range in AMH levels within each
group.
Table 44. Effect of women’s age on AMH levels.
Patient age (years) Mean ± Sem Range
26-30 (n=6) 48.9 ± 15.9 12.1 - 112.5
31-35 (n=17) 30.5 ± 6.4 3.26 - 106.3
36-39 (n=14) 17.3 ± 2.6 6.8 - 42.5
40+ (n=8) 12.9 ± 5.7 1.6 - 39.6
Figure 26. Changes in AMH levels with advancing age (dotted line representing the
linear trend line).
0.0
20.0
40.0
60.0
80.0
100.0
120.0
AM
H C
on
cen
tra
tio
n (
pm
ol/
ul)
Advancing age →
89
5.3.2 AMH and BMI
No correlation (r=-0.102, p=0.537) was present between patient BMI and their
baseline (day 2 menstrual cycle) AMH concentration (pmol/L) as shown in Figure 27.
Patient BMI was calculated using patient’s day 2 weight and height. Not all patient
BMIs were available for analysis (n=39). The average patient BMI for all patients that
achieved a successful pregnancy was 24.7, with a highly variable range between 18.0
and 36.1.
Figure 27. Patient BMI compared to baseline AMH concentration (dotted line
represents the linear trend).
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5.3.3 BMI and Age
To confirm that the significant relationship between AMH and age was not due to BMI
influence, patient age was plotted against their BMI (Figure 28) and only patients that
also has day 2 AMH levels were included in the analysis (n=39). No relationship existed
between age and BMI (r=-0.006, p=0.972).
Figure 28. Patient age compared to BMI (dotted line represents the linear trend).
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5.3.4 AMH and Medications
A table of medications taken by each patient in the cycle prior to their positive
pregnancy is listed in Appendix P. There were no trends between AMH levels and any
of the medications, including oral contraception. There were only two patients that
were taking oral contraception the month directly prior to their fertility treatment
(gestation week 0) and all other patients had been actively trying to conceive (had not
been taking the contraceptive pill).
To demonstrate the non-existent effect of stimulation drugs on AMH, the daily dose of
follicle stimulatory drug follitropin alfa (FSH) administered in IVF/ICSI, FET and OI/AIH
cycles, was compared against the mean percentage AMH change between gestation
week 4 and week of fetal heart detected by ultrasound (Figure 29). There was no
correlation between dosage of FSH and percentage AMH change in early pregnancy
(r=0.063, p=0.568). The average dose of FSH in each cycle group and the AMH levels at
gestation week 4 (after administration of this drug) is shown in Table 45.
Figure 29. Daily follitropin alfa levels (IU) administration compared to mean AMH
change (%) from gestation week 4 to week of fetal heart detected by ultrasound
(dotted line represents the linear trend).
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Table 45. Mean daily follitropin alfa dosage and the effect on serum AMH
concentrations (mean ± sem) in different cycle types at gestation week 4.
Cycle Type FSH Dose (IU) AMH (pmol/L)
Natural 0.0 ± 0.0 21.7 ± 4.7
IVF/ICSI 207.8 ± 23.7 13.3 ± 3.3
FET 43.8 ± 3.2 16.0 ± 2.1
AIH 39.6 ± 6.8 24.1 ± 5.4
OI 54.2 ± 10.5 37.2 ± 6.9
5.3.5 AMH and Fetal Sex
Of the 70 patients that achieved a successful pregnancy, a total of 30 fetal or baby
genders were identified at the time of data analysis, from either the 20 week
ultrasounds or births respectively. There was no relationship between the fetal/baby
gender and the changes in the mother’s AMH concentration during early pregnancy
(Figure 30). 54.5% (6/11) boys showed a decrease in mother’s AMH levels, compared
to 45.5% (5/11) that increased. Of the 19 girls, 12 (63.2%) had a decrease in the
mother’s AMH levels, compared to 7 (36.8%) that increased. Percentage AMH change
was calculated as the mean percentage change from gestation week 4 to 6.5.  Analysis
of AMH within this gestational time revealed gender was not a significantly
contributing factor (p=0.809) (Table 46).
Table 46. Repeated measures ANOVA for AMH gestation weeks 4 to 6.5 with gender
as between-subject factor.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
gender 0.602 10 96 0.809 0.059 6.018 0.295
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Figure 30. Percentage change in mother’s AMH levels during early pregnancy
compared to gender of fetus/baby.
5.3.6 AMH and Other Hormones
AMH was negatively correlated to P4 (r=-0.220, p=0.000,) and TSH (r=-0.155, p=0.001)
during gestation weeks 4 to 6.5 (Table 47).
Table 47. Hormone correlations during early pregnancy (n=472 - 488).
Correlation AMH hCG P4 E2 fT3 fT4 TSH
AMH 1.000 0.072 -0.220* -0.023 -0.003 0.076 -0.155*
hCG 0.072 1.000 0.032 0.234* -0.129* -0.098# -0.133*
P4 -0.220* 0.032 1.000 0.098# -0.014 -0.024 0.073
E2 -0.023 0.234* 0.098# 1.000 -0.121# 0.098# -0.072
fT3 -0.003 -0.129* -0.014 -0.121# 1.000 0.276* 0.217*
fT4 0.076 -0.098# -0.024 0.098# 0.276* 1.000 0.196*
TSH -0.155* -0.133* 0.073 -0.072* 0.217* 0.196* 1.000
*p<0.05, #p<0.005
AMH was negatively correlated with E2 (p=0.005), P4 (p=0.000), fT3 (p=0.026) and TSH
(p=0.000) when accounting for cycle types (Table 48). In addition, AMH was positively
correlated with hCG (p=0.001) when accounting for both cycle type and gestation
week (Table 48). However, since approximately half of the women had increasing AMH
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levels and half had decreasing AMH levels as gestation (and hCG) increased, the weak
correlation (r=0.142) between these two hormones was expected. Scatterplots were
generated to visualise any trends between those hormones that showed significant
interactions (Figures 31 - 36).
Table 48. AMH vs other hormones when accounting for cycle type and cycle type and
gestation week combined (n=674 - 728).
Correlation AMH (cycle) AMH (cycle & week)
E2 -0.108# -0.087*
P4 -0.171# -0.15*
hCG 0.039 0.142*
fT3 -0.082# -0.091#
fT4 -0.025 -0.023
TSH -0.160# -0.162#
*p<0.05, #p<0.005
Figure 31. AMH vs E2 accounting for cycle type.
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Figure 32. AMH vs P4 accounting for cycle type.
Figure 33. AMH vs hCG accounting for cycle type.
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Figure 34. AMH vs hCG accounting for gestation week.
Figure 35. AMH vs fT3 accounting for cycle type.
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Figure 36. AMH vs TSH accounting for cycle type.
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CHAPTER 6
THYROID HORMONE RESULTS
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6 Thyroid Hormone Results
6.1 Thyroid Levels Before and During Early Pregnancy
6.1.1 fT3 Levels Before and During Early Pregnancy
The mean fT3 concentration in patients during early pregnancy (gestation weeks 4 to
7) was 4.58 ± 0.02pmol/L, which was similar to the non-pregnant mean concentration
at gestation week 0 (4.61 ± 0.07pmol/L). Comparison of fT3 concentrations before
pregnancy (gestation week 0) to day of pregnancy test (gestation week 4) revealed no
significant difference (p=0.292) (Table 49). However, the concentration of fT3
decreased gradually during early pregnancy (gestation weeks 4 to 6.5) (Figure 37), (r=-
0.104, p=0.005). There was a significant difference noted in fT3 levels (p=0.003) when
accounting for week using ANOVA (Table 50). The fT3 levels (mean ± sem) and
confidence intervals for patients with serum samples measured at all gestation weeks
between 4 and 6.5 (n=55) are shown in Table 51.
Table 49. Repeated measures ANOVA for fT3 gestation weeks 0 vs 4.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 1.142 1 37 0.292 0.030 1.142 0.180
Figure 37. fT3 concentration (mean ± sem) from gestation weeks 0 - 7. Number of
patient samples available for analysis at each gestation week is shown within each
column.
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Table 50. Repeated measures ANOVA for fT3 gestation weeks 4 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 4.180 5 50 0.003 0.295 20.899 0.937
Table 51. fT3 levels (mean ± sem) and confidence intervals during early pregnancy.
Gestation Week Mean(pmol/L) Sem
95% CI
Lower Upper
4 4.69 a, b 0.07 4.54 4.83
4.5 4.64 0.06 4.52 4.77
5 4.61 0.06 4.48 4.74
5.5 4.55 0.06 4.42 4.67
6 4.53 a 0.06 4.41 4.65
6.5 4.50 b 0.06 4.39 4.61
Note – concentrations with same superscript are significantly different (p<0.05)
6.1.2 fT4 Levels Before and During Early Pregnancy
The mean fT4 concentration in patients from gestation weeks 4-7 was
14.9 ± 0.09pmol/L, which was comparable to the non-pregnant mean concentration at
gestation week 0 (15.1 ± 0.35pmol/L). Comparison of fT4 concentrations before
pregnancy (gestation week 0) to day of pregnancy test (gestation week 4) revealed no
significant difference (p=0.269) (Table 52).The concentration of fT4 did not vary
significantly over gestation weeks 4 to 6.5 (Figure 38) (r=0.023, p=0.526), however
when analysing fT4 levels between weeks using ANOVA (Table 53), there was a
significant difference noted (p=0.018) and this was due to a significant difference
between gestation week 4 and 5.5. The mean fT4 levels (±sem) and confidence
intervals for patients with serum samples measured at all gestation weeks between 4
and 6.5 (n=54) are shown in Table 54.
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Table 52. Repeated measures ANOVA for fT4 gestation weeks 0 vs 4.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 1.260 1 37 0.269 0.033 1.260 0.194
Figure 38. fT4 concentration (mean ± sem) from gestation weeks 0 - 7. Number of
patient samples available for analysis at each gestation week is shown within each
column
Table 53. Repeated measures ANOVA for fT4 gestation weeks 4 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 3.026 5 50 0.018 0.232 15.129 0.825
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Table 54. fT4 levels (mean ± sem) and confidence intervals during early pregnancy.
Gestation Week Mean(pmol/L) Sem
95% CI
Lower Upper
4 15.21 a 0.25 14.70 15.71
4.5 15.11 0.28 14.55 15.67
5 14.95 0.29 14.36 15.54
5.5 14.59 a 0.28 14.03 15.15
6 14.79 0.28 14.23 15.34
6.5 14.87 0.30 14.27 15.47
Note – concentrations with same superscript are significantly different (p<0.05)
6.1.3 TSH Levels Before and During Early Pregnancy
The mean TSH concentration in patients from gestation weeks 4-7 was
1.50 ± 0.04mU/L, which was comparable to the non-pregnant mean concentration at
gestation week 0 (1.45 ± 0.13mU/L). Comparison of TSH concentrations before
pregnancy (gestation week 0) to day of pregnancy test (gestation week 4) revealed no
significant difference (p=0.485) (Table 55). However, the mean TSH concentration
decreased significantly during early pregnancy (gestation weeks 4 to 6.5) (Figure 39)
(r=-0.123 p=0.013). There was a significant difference noted in TSH levels (p=0.009)
when accounting for week using ANOVA (Table 56). The mean TSH levels (± sem) and
confidence intervals for patients with serum samples measured at all gestation weeks
between 4 and 6.5 (n=55) are shown in Table 57.
Table 55. Repeated measures ANOVA for TSH gestation weeks 0 vs 4.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 0.498 1 37 0.485 0.013 0.498 0.106
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Figure 39. TSH concentrations (mean ± sem) from gestation weeks 0 - 7. Number of
patient samples available for analysis at each gestation week is shown within each
column.
Table 56. Repeated measures ANOVA for TSH gestation weeks 4 to 6.5.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
week 3.476 5 50 0.009 0.258 17.380 0.881
Table 57. TSH levels (mean ± sem) and confidence intervals during early pregnancy.
Gestation Week Mean(mU/L) Sem
95% CI
Lower Upper
4 1.71 a, b 0.12 1.48 1.94
4.5 1.65 0.11 1.43 1.87
5 1.57 0.11 1.35 1.79
5.5 1.54 0.10 1.34 1.73
6 1.45 a 0.10 1.26 1.65
6.5 1.42 b 0.12 1.17 1.66
Note – concentrations with same superscript are significantly different (p<0.05)
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6.2 Thyroid Markers and Other Hormones
TSH, fT3 and fT4 were all negatively correlated to hCG. TSH and fT3 were negatively
correlated to E2 and fT4 positively correlated to E2, although this relationship was
extremely weak (r=0.098). fT3, fT4 and TSH were all positively correlated with each
other (refer to Table 47). All significant correlations were weak and were further
investigated by accounting for cycle type (Table 58).
A weak positive correlation existed between TSH levels and P4 when accounting for
cycle type (r=0.223, p=0.000). fT3 and TSH were negatively correlated with hCG,
although neither were strong correlations (r=-0.123 and r=-0.131 respectively). All
thyroid markers remained positively correlated with each other (p=0.000) when
accounting for cycle type, although still a weak effect (r≤0.290). fT4 was no longer
significantly correlated to hCG when accounting for cycle type. fT3 and fT4 were also
not significantly correlated to E2 when accounting for cycle type.
Table 58. Thyroid vs other hormones accounting for cycle type (n=485 – 728).
Correlation fT3 fT4 TSH
E2 -0.034 0.063 -0.008
P4 -0.081 0.082 0.223#
hCG -0.123# -0.037 -0.131#
fT3 1.000 0.290# 0.186#
fT4 0.290# 1.000 0.175#
TSH 0.186# 0.175# 1.000
#p<0.005
When the same partial correlations were performed, accounting for both cycle type
and gestation week (Table 59), there was only one discernible change (from the
significant relationships between hormones when accounting for cycle type alone) –
fT3 was significantly negatively correlated to P4, but only a very weak effect size (r=-
0.090).
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Table 59. Thyroid vs other hormones accounting for cycle type and gestation week
(n=485 – 728).
Correlation fT3 fT4 TSH
E2 -0.021 0.058 -0.013
P4 -0.090* 0.080 0.218#
hCG -0.091* -0.012 -0.172#
fT3 1.000 0.293# 0.186#
fT4 0.293# 1.000 0.175#
TSH 0.186# 0.175# 1.000
*p<0.05, #p<0.005
Scatterplots were generated to visualise any trends between those hormones that
showed significant interactions (Figures 40 -46).
Figure 40. fT3 vs P4 accounting for cycle type.
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Figure 41. TSH vs P4 accounting for cycle type.
Figure 42. fT3 vs hCG accounting for cycle type.
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Figure 43. TSH vs hCG accounting for cycle type.
Figure 44. fT3 vs fT4 accounting for cycle type.
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Figure 45. TSH vs fT3 accounting for cycle type.
Figure 46. TSH vs fT4 accounting for cycle type.
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6.3 Thyroid Levels in Viable vs Nonviable Pregnancies
The levels of all thyroid hormones were not discernible across gestation weeks 4 to 6.5
when accounting for pregnancy outcome. Viability was analysed as an independent
factor/between subjects effect and the variances in thyroid hormones between viable
and non-viable pregnancies were non-significant (Tables 60 - 62).
Table 60. Repeated measures ANOVA for fT3 gestation weeks 4 to 6.5 with viability
as between-subject factor.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
viability 0.275 5 60 0.925 0.022 1.374 0.113
Table 61. Repeated measures ANOVA for fT4 gestation weeks 4 to 6.5 with viability
as between-subject factor.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
viability 0.819 5 60 0.541 0.064 4.093 0.273
Table 62. Repeated measures ANOVA for TSH gestation weeks 4 to 6.5 with viability
as between-subject factor.
Effect F
Hypothesis
df
Error
df Sig.
Partial Eta
Squared
Noncent.
Parameter
Observed
Power
viability 0.330 5 60 0.893 0.027 1.652 0.127
28 patients (32.9%) in this study at one or more points during their pregnancy had a
TSH measurement >2.5mU/L and of these patients, 6 (7.1%) also had at least one TSH
measurement >4.0mU/L. 3 patients (3.5%) had viable pregnancies and 3 patients
(3.5%) miscarried with elevated TSH levels (>4.0mU/L). There were not sufficient
numbers for a proper statistical analysis, although this data showed a notable
miscarriage trend with 50% of patients having a TSH value over 4.0mU/L.
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6.4 Thyroid Reference Ranges Before and During Early Pregnancy
There were two women who tested positive for TPOAb, with levels of 85.2U/ml and
607.9U/ml. Both women had normal fT3, fT4 and TSH levels (within the reference
ranges determined for each gestation week in Tables 63 – 65) and viable pregnancies.
These two patients were excluded from all thyroid hormone analyses and prior to
calculating reference ranges. All other women in the study tested negative for TPOAb
(<28U/ml) and serum samples from these women were used to calculate reference
ranges for fT3, fT4 and TSH for gestation weeks 0 – 7 (Tables 63 – 65 and Figures 47 –
49).
Table 63. Maximum, minimum, median, mean and 2.5th – 97.5th percentile ranges for
fT3 (pmol/L) from gestation weeks 0-7.
Week 0 2 3 4 4.5 5 5.5 6 6.5 7
n 37 66 69 69 69 69 68 67 55 21
Maximum 5.43 5.78 5.81 5.95 5.78 5.67 5.35 5.70 5.47 5.49
97.5th 5.32 5.67 5.61 5.76 5.68 5.52 5.30 5.26 5.21 5.42
Median 4.65 4.71 4.64 4.66 4.66 4.58 4.63 4.54 4.48 4.52
Mean 4.61 4.68 4.62 4.67 4.63 4.59 4.52 4.52 4.49 4.57
2.5th 3.72 3.91 3.92 3.89 3.79 3.76 3.61 3.93 3.71 4.15
Minimum 2.97 3.84 3.52 3.83 3.58 3.58 3.31 3.81 3.59 4.14
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Figure 47. 2.5th – 97.5th percentile ranges for fT3 from gestation weeks 0 - 7 (error
bars represent maximum and minimum values).
Table 64. Maximum, minimum, median, mean and 2.5th – 97.5th percentile ranges for
fT4 (pmol/L) from gestation weeks 0-7.
Week 0 2 3 4 4.5 5 5.5 6 6.5 7
n 37 66 69 69 69 69 68 67 55 21
Maximum 20.88 20.06 20.92 19.24 20.66 19.45 19.28 19.80 20.50 18.52
97.5th 19.09 19.37 18.59 18.51 19.37 18.59 19.05 18.93 18.25 18.52
Median 14.96 14.48 15.12 14.90 15.15 14.75 14.66 14.58 14.99 15.14
Mean 15.09 14.46 14.91 15.09 15.11 14.90 14.58 14.70 14.92 15.22
2.5th 11.62 10.28 11.23 11.20 11.31 11.13 10.18 11.76 11.02 10.89
Min 10.98 9.97 10.75 10.42 9.46 9.99 9.73 9.99 10.22 10.40
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Figure 48. 2.5th – 97.5th percentile ranges for fT4 from gestation weeks 0 - 7 (error
bars represent maximum and minimum values).
Table 65. TSH reference ranges (mU/L) from gestation weeks 0-7.
Week n geometric mean (limits of 1sd) Range (min-max)
0 36 1.27 (0.74 - 2.20) 0.49 - 3.79
2 64 1.14 (0.67 - 1.93) 0.32 - 2.99
3 67 1.48 (0.88 - 2.42) 0.51 - 3.99
4 67 1.48 (0.89 - 2.44) 0.41 - 4.20
4.5 67 1.40 (0.86 - 2.36) 0.43 - 4.24
5 67 1.37 (0.81 - 2.25) 0.43 - 3.44
5.5 66 1.30 (0.79 - 2.20) 0.44 - 3.19
6 65 1.28 (0.76 - 2.15) 0.42 - 3.47
6.5 54 1.17 (0.62 - 1.85) 0.27 - 4.93
7 21 1.37 (0.75 - 2.11) 0.53 - 3.62
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Figure 49. 2.5th – 97.5th percentile ranges for TSH from gestation weeks 0 - 7 (error
bars represent maximum and minimum values).
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7 Discussion
7.1 Reproductive Hormones in Early Pregnancy
Reproductive hormones such as oestradiol (E2), progesterone (P4) and human
chorionic gonadotropin (hCG) are measured routinely during ART to assess ovarian
responses to stimulation drugs, time ovulation and evaluate the normal biological
processes during pregnancy. By evaluating the levels of these hormones in all women
in this present study, these important events could be tracked and the progress of
each pregnancy monitored to distinguish between an ongoing or viable pregnancy and
a nonviable pregnancy or miscarriage.
The Siemens XP reproductive hormone assays were all shown to be reliable in the
range of hormone concentrations measured, when performing serial dilutions.
Oestradiol had the highest variability, particularly at very low or high concentrations.
Therefore care must be taken when interpreting patient results by referring to the
Siemens XP measurements uncertainty for each hormone.
7.1.1 Oestrogen
Oestrogen is released by developing ovarian follicles and by the corpus luteum and
placenta during pregnancy. Although oestrogen is an essential steroid hormone which
works in conjunction with progesterone to prepare the endometrium for embryo
implantation, little is understood of its function during pregnancy [169, 170]. The three
main naturally occurring oestrogens in women are oestrone (E1), oestradiol (E2), and
oestriol (E3). E2 is the predominant oestrogen in terms of its activity and serum levels
[171]. There is limited available data on maternal serum oestradiol concentrations
prior to gestation week 10 [172], however the data available from the first trimester
(gestation week 12) through to term documents a steady rise [173, 174]. The mean
oestradiol levels measured during this study, showed levels rising significantly with
increasing length of gestation, starting from 1367.7pmol/L at gestation week 4 and
reaching a level of 3644.1pmol/L at gestation week 7, which is consistent with the
trend in the later stages of pregnancy.
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7.1.2 Progesterone
It is well known that adequate progesterone production by the corpus luteum is vital
to the maintenance of early pregnancy. In a naturally occurring pregnancy,
endogenous production of progesterone from the corpus luteum up to gestation week
7 is usually sufficient to support the growing fetus [175]. Of the 14 naturally occurring
viable pregnancies observed in this present study, 50% were not given luteal and early
pregnancy progesterone support and had a mean concentration of 121.4nmol/L at
gestation week 4. Women who were having blood samples taken to track their natural
cycle, or after a frozen embryo transfer or artificial cycle (AI or OI), were offered
progesterone support if their levels were below 70nmol/L at gestation week 3 as it is
known to improve pregnancy outcome [176, 177]. The clinic where the present study
was undertaken has a  policy for all women following transfer of an embryo in IVF/ICSI
cycles  to supplement with progesterone until at least gestation week 7. Progesterone
concentrations remained constant during early pregnancy for all cycle types, with a
mean of 177.1nmol/L from gestation week 4 to 7.
7.1.3 Human Chorionic Gonadotropin
During the first trimester of pregnancy, serum hCG levels follow an exponentially
increasing pattern, typically doubling every 2 days [178] and reaching a plateau
between gestation weeks 8 – 10 [179]. The function of hCG in early pregnancy is well
known, maintaining corpus luteum progesterone production, thereby supporting the
development of the embryo [180].
The current study tracked the classical pattern of hCG in individual women to establish
an ongoing or viable pregnancy. The maternal serum levels of hCG in viable
pregnancies increased significantly with gestational age, as expected, reaching levels of
over 50,000mU/ml at gestation week 6.5. Most patients did not have a blood sample
taken after this point following detection of a fetal heart at ultrasound. There were a
total of 15 pregnancies (17.6%) that miscarried in the study, which displayed
suboptimal hCG levels and were confirmed nonviable at ultrasound when no fetal
heartbeat was present.
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7.2 AMH
7.2.1 Sample Storage and AMH Stability
Beckman Coulter advises that reliable AMH results are only obtained by following the
precise laboratory techniques and adhering to the package instructions for the Gen II
ELISA. The instructions recommend transferring at least 500µL of cell-free serum to a
secondary storage tube within two hours of centrifugation, storing the sample at 2 to
8°C and performing the assay within 48 hours - or alternatively freezing at -20°C.
The issue with collecting samples for this present study was that samples were
collected retrospectively, following recruitment of the patient after a positive
pregnancy test, by which time the samples had already been centrifuged and stored in
their original collection tube for 7 days at 2 to 8°C, then frozen at -20°C (Fertility
North’s standard protocol for sample storage). Even though AMH levels have been
shown to remain stable at room temperature over 5 days [181] and all samples were
stored at 2 to 8°C within 4 hours of collection, protocol variations to the storage of
patient serum samples needed to be validated to ensure the AMH concentrations were
reliable in this study.
This study confirmed that storage of centrifuged blood in the original collection tube
and subsequent storage in the refrigerator for up to 7 days does not affect AMH
concentration as measured using the Beckman Coulter AMH GEN II assay. Other
studies have also reported AMH to be stable for up to 7 days at 2 to 8°C [182] and up
to 3 months at 2 to 8°C [183].
There was also no effect on serum AMH levels after freezing for 1 week, with no
significant difference observed between levels before and after freezing of samples.
Only a 1% variation in AMH levels has previously been reported between fresh serum
samples and samples that have been frozen [182]. Further investigation may be
warranted to determine AMH stability over extended storage periods at -20°C. Patient
samples in this present study were frozen in batches so any differences seen in AMH
levels were not due to varied storage conditions between samples.
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Storage methods that deviated from the manufacturers recommendations had
minimal effect on AMH concentrations. This validation allowed the collection of blood
samples for routine patient monitoring to be stored simply in the laboratory for up to
one week, whilst suitable patients were identified, invited and enrolled into the
research project.
7.2.2 Assay Performance
The development of the new AMH Gen II assay by Beckman Coulter involved a merging
of the Diagnostic Systems Laboratories (DSL) antibodies and the Beckman Coulter
Immunotech assay calibration [184]. The interpretation of AMH values obtained from
each of these assays has been compared and reviewed [185, 186], with a strong
correlation between all three assays reported.
When using any immunoassay, assessing its variability is important to determine
possible sources of technical error. This study used pooled serum samples as external
controls in each of the patient assays (in addition to the manufacturer’s artificial
quality controls), to generate a precision profile for the Beckman Coulter AMH Gen II
ELISA that reflected the nature of the samples being tested. Higher between-assay
variability compared to intra-assay variability highlighted the importance of measuring
AMH in serial samples from individual patients in one assay to minimise this source of
error.
This current study confirms that the new Gen II assay performs well when measuring
patient samples in one assay, even with deviations from the manufacturer’s
instructions regarding sample preparation. However, all laboratory methods have
limitations when it comes to the reliability of measuring a hormone in patient samples.
This study demonstrated that very low or very high AMH concentrations are subject to
greater variability even when run in the same assay, indicating that care must be taken
when assessing small changes between serial samples that fall into these ranges.
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7.2.3 AMH in Early Pregnancy
There has been much debate over the last decade with regard to AMH levels in varying
physiological states, such as different stages of the menstrual cycle and during
pregnancy. The general consensus of AMH in the past is that it is a relatively stable,
unchanging hormone and a reliable indicator of ovarian reserve. During pregnancy,
serum AMH levels in the first trimester have been reported as comparable to non-
pregnant levels [46, 57, 58]. This is consistent with the findings in this current study
when baseline AMH levels were compared to gestation week 4 levels in natural cycle
patients, showing no significant variation. Some studies have reported a decline in
AMH levels with advancing gestational age [58, 59], however, in these studies AMH
levels were measured only once in each trimester. Cross sectional studies of AMH are
also limited by the fact that different women of the same age can show substantial
variations in their AMH levels [57, 59, 187]. These studies report the mean AMH
concentration at one particular time point and compare this mean to another time
point between different groups of women. When analysed in this fashion, it is
unsurprising that any true changes in AMH over time become undetectable. This study
demonstrated this phenomenon by comparing the mean AMH levels of all patients at
each gestation week, resulting in no apparent changes in AMH over time. This present
study also demonstrated large variations in both baseline AMH levels and gestation
week 4 (pregnant) levels between women in different age and cycle groups.
An important strength of this study was that we were able to follow changes in AMH in
individual women across early pregnancy and this is the first study that we are aware
of, that provides data of this nature. It showed that AMH levels in pregnant women do
not remain stable but consistently change, moving up or down for different women,
irrespective of treatment cycle (and FSH stimulation). These findings contradict the
theory that AMH levels reflect the FSH-independent noncyclic growth of small ovarian
follicles. This study suggests that ovarian quiescence may not be absolute during
pregnancy, or that there may be a reduction in the number of follicles secreting AMH
during pregnancy in some women but not in others. The hypogonadotropic status in
pregnancy does not seem to affect AMH levels consistently. There could be other
unidentified factors that are contributing to the increase in AMH observed during
some pregnancies and not others. This study also demonstrated that a woman’s
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baseline (non-pregnant) AMH concentration had no effect on whether her AMH levels
increased or decreased during pregnancy. It may be that the increase in AMH levels in
some women are attributable to cyclic follicle growth and recruitment during
pregnancy, therefore it may be useful to monitor this during early pregnancy via
ultrasound.
In some respects these findings are not surprising as many of the previously accepted
concepts about AMH and its “stability” and what physiological changes may affect
AMH are also being challenged. For example it is now known that patients do have
changes in AMH during normal menstrual cycles, with acute illness, smoking and that
there are also minor circadian and seasonal changes. The findings from our study on
the variability of AMH in early pregnancy, with some individuals’ AMH levels rising and
others falling, suggest that factors affecting AMH are as yet poorly understood. This
study also suggests that further research into factors affecting AMH (including in
pregnancy and miscarriage) are required.
7.2.4 AMH in ART cycles
Often a patient’s prescribed treatment/cycle type will depend on a number of factors,
not just AMH alone. However, despite the large range of AMH levels within each cycle
type, the average level at baseline was indicative of the ovarian function of most
women in the group. For example, older women with low ovarian reserve (AMH
<5pmol/µL) typically undergo IVF or ICSI treatment, compared to women with large
numbers of small follicles (eg PCOS patients) that exhibit high AMH levels (>30pmol/L)
and are recommended for ovulation induction (to stimulate the maturation of a follicle
for ovulation). Women with normal ranges of ovarian reserve (AMH ~20pmol/µL)
typically undertake natural tracking cycles to correctly time ovulation, or possibly
artificial insemination. This study confirmed significant differences in AMH levels
between IVF/ICSI cycle patients and patients in all other cycle groups (FET, OI/AIH and
Natural).
The changes in AMH levels between baseline and gestation week 4 also reflected the
treatment or cycle type. For instance, an increase (although non-significant) in AMH
levels in IVF/ICSI patients was noted in those women receiving ovulation stimulation
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medication. This treatment is expected to result in high numbers of follicles developing
for collection, and it is likely that each developing follicle releases AMH. However most
women undergoing IVF usually have a lower ovarian reserve and hence small changes
in AMH are trivial. In contrast, OI and FET patients showed a significant decrease in
AMH levels between gestation weeks 0 and 4, which can be explained by one or more
immature or small follicles growing to dominancy and ceasing to release AMH (AMH is
only produced by the granulosa cells of preantral and small antral follicles, and not in
primordial or atretic follicles [41]).  Natural cycle patients typically show little change in
AMH levels between gestation week 0 and 4, when there is no ovarian stimulation.
However this study did note that AMH levels decrease more often in natural
pregnancy cycles (p=0.028), with 70% (11/15) of women following this trend. This is
consistent with other studies that have investigated AMH levels in normal (natural)
pregnancies [58, 59] although this trend was seen in later stages of pregnancy. AMH
has long been used as a predictive marker of ovarian response to IVF or ICSI treatment,
with low responders (low AMH levels) typically assigned higher doses of FSH [188] to
stimulate the growth of follicles.
7.2.5 AMH Patterns in Viable and Nonviable Pregnancies
With most of the viable pregnancies, AMH followed one of two patterns from the time
of the positive pregnancy test to the detection of fetal heartbeat measured by week 7.
Over this time period, AMH levels measured at each time point followed either a
progressive  upward or downward trend, and continued to increase or decrease as the
gestation progressed.
A discernible difference between the pregnancies that were maintained (viable) and
those that miscarried was the unpredictable nature of the AMH levels measured at
each time point for the women that miscarried. However, when running posthoc
analysis of gestation week with viability as a between subject factor, there were no
significant differences in AMH levels between gestation weeks 4 to 6.5. It is difficult to
predict whether the changes in AMH levels are in some way contributing to the
pregnancy itself, or whether the levels are a consequence of an unknown factor during
the pregnancy. It is very interesting that all 15 nonviable pregnancies had sporadic
changes in AMH levels, constantly rising and falling from week to week. In contrast,
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viable pregnancies followed a steadily increasing or decreasing trend of AMH. No other
study has investigated the pattern of AMH change in individual women during a
miscarriage, and the results of this study should be confirmed in a larger cohort of
women to better understand what may be causing the irregular ‘spikes’ and ‘dips’ in
AMH levels.
AMH has been investigated by other researchers to determine its usefulness in
predicting oocyte and embryo quality and subsequent pregnancy rates [189, 190],
however the results are still controversial. Quite often female age, which is strongly
related to pregnancy rates, is omitted as a contributor to prediction models [191, 192].
This current study did not have high numbers of miscarriages, so the power to predict
pregnancy outcome based on the changes in AMH levels was low. However, age was
not seen as a contributing factor to pregnancy outcome, with only two years
difference in the mean age between viable and nonviable pregnancies. In addition,
there were miscarriages in all cycle groups apart from AIH cycles.
There have been numerous studies that have looked at AMH levels in predicting an
ongoing pregnancy, with conflicting results. Although age is accepted as the best
predictor of a successful (ongoing) pregnancy, some studies report that ovarian
reserve testing such as AFC or AMH do not improve prediction [189, 193-195], whilst
others note that levels of these markers can predict the risk of miscarriage [188, 196-
199]. Since this study observed significant differences between viable and non-viable
pregnancies, it would be worthwhile to investigate this further in a larger longitudinal
cohort.
7.2.6 AMH and Age, BMI and the Menstrual Cycle
The relationship between age and female fertility is well established [131, 200, 201],
with AMH levels declining with advancing age. This study reconfirmed the strong
correlation between age and AMH, by comparing the mean baseline AMH (day two of
the menstrual cycle) to patient age. Women were assigned to four age categories (26-
30 yrs, 31-35 yrs, 36-39yrs and 40+ yrs) to demonstrate the significant decrease in
mean AMH levels, despite the highly variable range of levels within each age group.
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High inter-individual variability for AMH is not unexpected, since the hormone is
widely used as a biomarker of ovarian reserve in women [202].
There are many factors that have been shown to affect a woman’s ovarian reserve,
such as PCOS [203, 204] and ethnicity [205, 206].  This present study reported no
significant association between AMH and BMI, which is consistent with other studies
[181, 207] and contradictory to others that have reported negative associations [208,
209]. BMI was not found to correlate with patient age, which is supported by a recent
study [210], and therefore was excluded as a factor affecting the relationship between
age and AMH.
The issue of whether or not AMH levels fluctuate during the menstrual cycle is a highly
controversial one. One study found that AMH levels can vary as much as 80% in one
cycle [49], with a significant decrease of the mean AMH concentration in the luteal
phase compared to the follicular phase. Other studies have shown that AMH levels do
not significantly vary in the menstrual cycle [211-214]. In the present study, a blood
sample was collected on day two (follicular phase), day of ovulation and mid-luteal
phase to assess the changes in AMH levels. All time points (between baseline and
ovulation or mid-luteal) were significantly correlated. For example, a low baseline AMH
would be indicative of a low AMH level at time of ovulation. AMH levels were
observed to peak at ovulation (gestation week 2) and decrease at mid-luteal (gestation
week 3) across all types, which is consistent with a recent study that reported
significant variation during the menstrual cycle [49]. Although the difference in AMH
levels between ovulation and mid-luteal was non-significant, there was a significant
difference seen between levels at ovulation and gestation weeks 5.5 and 6, as well as
between levels at mid-luteal and gestation week 6.
The limitation of this analysis was that the mean percentage change of all patient AMH
levels did not reflect the pattern seen in each individual woman. In other words, when
the percentage AMH changes for each woman were observed between baseline and
ovulation and between baseline and mid-luteal, some women had increasing AMH
levels whilst others had decreasing levels. Also, there is an important difference
between the patients in this study compared to previous studies that have looked at
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AMH levels in the menstrual cycle – and that is that fertilization has usually occurred a
few days post ovulation – in fact, in the case of all patients excluding natural and
artificial insemination patients, a precise day of embryo transfer is known. Therefore,
the decrease seen in AMH levels at the mid-luteal time point from ovulation cannot be
directly compared to the AMH changes at the same time-point in non-pregnant
women.
7.2.7 AMH and Other Hormones
There has been much speculation as to whether AMH levels are regulated by paracrine
or autocrine functions. This study found that AMH was independently associated with
the reproductive hormone oestradiol during pregnancy, which is supported by other
researchers [58, 215]. One study observed a correlation between E2 rising and AMH
declining during IVF stimulation [216], which this present study did not observe in the
follicular to luteal phase of the menstrual cycle in IVF/ICSI patients. AMH had a weak
negative correlation with P4 and TSH. The weak relationship with P4 could be
explained by the higher levels of support given to IVF/ICSI patients (who tend to have
lower AMH levels to begin with) compared to those patients with relatively normal
AMH levels in natural cycles that are not given any support (ie AMH is lower when P4
levels are higher, or P4 levels are lower when AMH levels are higher). However, most
women in this study were given progesterone support and there were still some
women who had increasing and some with decreasing AMH levels during pregnancy.
TSH decreased significantly with pregnancy and given that about half of the patients
also had a gradual increase in AMH levels, it is not surprising that there was a
relationship noted. However, the weak relationship that was shown between these
two hormones was not a large effect (only about 2.5% of the variability can be
explained by one factor significantly affecting the other). AMH did not correlate with
fT3 or fT4.
This study also suggests that AMH expression is not regulated by gonadotrophins
alone, since AMH levels increased in some women and decreased in others, whilst FSH
and LH levels are suppressed during pregnancy, and hCG increases in all pregnancies
(no significant correlation exists between AMH and hCG).
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7.2.8 AMH and Medications
Different fertility treatments involve various combinations and concentrations of
medication, depending on the cycle type and individual response. Each woman has a
tailor-made repertoire of drugs which is decided by their medical practitioner. This
study found no significant correlations between the ovarian stimulation drug dosage
and the trend in AMH levels, which is consistent with other findings [159, 217]. Despite
large differences in the combinations and dosages of patient medications, there were
still women within each treatment group that exhibited a rise in AMH levels, whilst
some showed decreases.
One study showed that AMH levels were suppressed with the use of oral
contraception and then rose immediately after its cessation [50], however this study
was only performed on two women that took oral contraception for a long time period
(over 12 years). Most patients in this study were not taking oral contraception in the
month prior to their pregnancy - indeed most patients attending fertility clinics have
issues conceiving and have been actively ‘trying’ for a long period (with no
contraceptive use). However, there were a few patients who were prescribed oral
contraception in the few months prior to their ‘pregnancy cycle’ in an attempt to
regulate their cycles, but these patients did not exhibit the same trend in AMH levels.
Similarly, some women who have never taken oral contraception exhibited increases
and others had decreases in their AMH levels, so it can be assumed that oral
contraception was not a contributing factor in these two cases. However, since there
were only two patients in this study that used oral contraception, the numbers were
too small to analyse whether there was any significant effect on AMH levels.
7.2.9 AMH and Fetal Gender
This study found that there was no association between the gender of the fetus and
the trend in AMH levels. As a male embryo develops, the Sertoli cells secrete around
1000 fold higher AMH levels than in females, so it would have been interesting to note
whether AMH crossed the placental barrier into the maternal blood to cause a rise in
AMH if the fetus was male. However, comparison between gender and AMH levels
proved insignificant. This result is consistent with other findings [218].
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7.3 Thyroid Hormones
7.3.1 Assay Performance
The performance of direct free thyroid hormone assays (fT4 and fT3) and the use of
dialysis or ultrafiltration methods have been debated [219]. Automated fT4
immunoassays in particular can be subject to interference, particularly in altered
physiological states such as pregnancy, which is associated with altered protein
binding [220]. Although results between various immunoassays and methods have
been reported as comparable in one study [221], others have reported substantial
differences [219, 220, 222]. However, direct free thyroid assays (fT4, fT3) are in
common use and currently used for clinical management, therefore were utilized for
this study.
The reliability of the Siemens XP automated fT3, fT4 and TSH assays were investigated
to validate patient results and establish gestational-age specific reference ranges.
Control pooled serum samples were used in all assay runs in addition to three
manufacturers controls to compare inter- and intra-assay variability. The CVs of fT3
serum and artificial QCs were comparable between assays, whilst the CVs for fT4 and
TSH serum controls were notably higher between assays than within the same assay
(7.48% vs 5.23% and 9.94% vs 2.75% respectively). This highlighted the importance of
running patient samples in one batch to minimize this source of analytical variation.
7.3.2 Maternal Thyroid Changes during Pregnancy
During the first trimester, maternal changes in thyroid hormones are well known – the
rise in hCG results in very mild and transient increases in fT4 and fT3, which via a
negative feedback, leads to a decrease in TSH [118, 223]. An increase in free T4 has
been noted toward the end of the first trimester by some authors [224] , but not by all
studies [225], and it is important to note that measurement of thyroid hormones in
pregnancy is complex. Factors such as rising Thyroid Binding Globulin (TBG) and falling
albumin levels can change binding dynamics [226] and there are unknown effects on
direct free thyroid hormone assays. Furthermore it is known that levels of fT3 are
largely determined by peripheral de-iodination of fT4 [77, 227]. Two main types of de-
iodinase are found – Type I in the liver, kidney and thyroid and this enzyme determines
measured serum levels of fT3. Type II de-iodinase is found in the pituitary and may be
differently regulated from Type I. This differential regulation of the two de-iodinases
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can explain apparent “discrepancies” in fT4, fT3 and TSH levels. These discrepant
values are common in clinical practice and can occur in acute illness  such as ‘sick
euthyroid syndrome’ [228, 229] or in starvation [230], uraemia [231] or diabetes [232].
Despite the active thyroid changes that occur in the first trimester and the importance
to fetal development, most published studies during this time are cross-sectional and
do not look at any time points prior to gestation week 8. The current study focused on
gestational weeks 4 to 6.5 (week 7 was eliminated from the analysis due to low patient
numbers), with blood sampling twice weekly in individual women in order to establish
longitudinal reference ranges in early pregnancy.
In this study, there were no significant changes documented in fT4 levels during the
time period, with mean concentrations from gestation week 4 to 6.5 similar to the
non-pregnant concentration at week 0. We did note however, gradual small but
significant decreases in fT3 from gestation weeks 4 to 6.5. As expected, TSH
concentration dropped significantly with gestational age, from gestation week 4
onwards. This strongly correlated with the rapid rise in hCG during this time, which is
consistent with the trend in the first trimester of pregnancy [223]. The relationships
between each of the hormones fT3, fT4 and TSH during gestation were demonstrated
to be statistically significant. There were no significant differences between non
pregnant (gestation week 0) and pregnant (gestation week 4) fT3, fT4 or TSH levels.
However, there was a significant difference between TSH levels at gestation week 0
compared to gestation week 6.5.
The lack of change in fT4 is not surprising as many authors note that changes in thyroid
hormones are minimal because the compensatory decrease in TSH occurs very rapidly
to re-establish normal free thyroid hormones. The issues of the type of measurement
of fT4 in pregnancy also need to be considered and to more exactly document changes
to free T4, complex and expensive methods such as ultrafiltration or dialysis have been
proposed. However these are not practical for clinical practice.
The reduction in fT3 initially appeared surprising. However when considering the
changes that occur in activity of the Type I de-iodinase in states of starvation and in
diabetes these changes are not dissimilar to those that occur in early pregnancy.
128
Early pregnancy is a state where fasting rapidly results in low glucose due to the high
levels of insulin and activity of lipolytic hormones. In contrast, after a meal pregnant
women are more likely to be hyperglycaemic (similar to diabetic women) as they have
higher levels of insulin but concurrent insulin resistance.  A reduction in Type I de-
iodinase activity may result in reduced fT3 levels. However, in these situations, Type II
de-iodinase which controls pituitary T3 levels, is not affected. As such, normal/high
levels of fT4 in the pituitary are converted normally to fT3 and this results in reduction
of TSH from the hypothalamic –pituitary axis. It is also interesting that fT3 levels
decreased in early pregnancy, a time when women often experience nausea and/or
vomiting which puts the body in a state similar to starvation, resulting in decreased
peripheral conversion of T4 to T3.
7.3.3 Thyroid Markers in Viable and Nonviable Pregnancies
The incidence of miscarriage was investigated and no measures of thyroid function
(fT3, fT4, TSH or TPOAb) appeared to have an effect on the pregnancy outcome,
however numbers of miscarriages were small. There have been numerous studies that
have investigated the role of thyroid hormones in maintaining early pregnancy or in
recurrent miscarriage [233-240] and this literature suggests there is an increased
association with miscarriage and abnormal levels of thyroid hormones. A relationship
between elevated TSH serum levels and risk of miscarriage has been reported
previously [86], however rates of subclinical hypothyroidism during pregnancy are very
low, between 2-3% [85]. The results of this present study showed a slightly higher rate
of hypothyroidism (7.1%), defined at TSH levels >4.0mU/L. Half of the patients (n=3)
with raised TSH levels resulted in miscarriage and half (n=3) were viable pregnancies.
So although not statistically significant due to small numbers, the data suggests that
there is a trend present with regards to elevated TSH and risk of miscarriage. There
were only two patients that tested positive for TPOAb and both women had a
successful pregnancy. Thyroid hormones for both these women were within normal
ranges during early pregnancy, however it is important to note that TPOAb positive
women are at a higher risk for developing postpartum thyroiditis. Therefore, both of
the women’s treating doctors were made aware of their thyroid autoantibody results
so that their thyroid hormones could be further monitored.
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7.3.4 Thyroid Markers and Other Hormones
The weak positive correlation that existed between TSH and fT3 levels and P4
(accounting for cycle type and gestation week) can be attributed to the increasing
levels of progesterone support that is administered in most ART pregnancies,
especially in IVF/ICSI cycles. fT3 and TSH were negatively correlated with hCG, which is
expected since hCG is well-known to increase as the pregnancy progresses [241] and
both fT3 and TSH were found to decrease gradually during pregnancy. It is unlikely that
these significant effects are a consequence of a direct interaction between the
hormones, with very weak effect sizes (r2<10%). All thyroid markers remained
positively correlated with each other. There is no literature that examines the
interaction between fT3, fT4 and TSH during this early gestation period, so it is difficult
to establish what are considered expected changes in these levels. It is known that
serum fT3 and fT4 levels increase slightly at 10-12 weeks when hCG is at its highest,
but remain within normal limits [242], whilst TSH concentrations decrease, fT3 and fT4
levels also decrease later in pregnancy when hCG starts to decline. Furthermore, the
changes in thyroid hormones that take place at different time points during gestation
are a result of complex effects that may be seen only momentarily. Hence the gradual
decrease in fT3 that was observed during gestation weeks 4 to 6.5 is not likely to have
any effect on the pregnancy itself, especially when levels are within expected ‘normal’
limits.
7.3.5 TPOAb in Pregnancy
Thyroid autoantibody measurement is a common marker of autoimmune thyroid
disease, therefore women who tested positive for TPOAb were excluded from all
thyroid data analyses. This study found only 2 women (2.35%) tested positive for
TPOAb, which is lower than another study that reported the prevalence of TPOAb as
5.4% in women undertaking ART [243], although this was in a larger cohort (n=688).
Of the two women who were TPOAb positive, one woman had undergone a FET cycle
and the other an OI cycle. Both women had thyroid levels within the ‘normal’ ranges
determined in this study and both pregnancies were viable (single fetal heartbeat
detected). Interestingly though, the woman that had a successful FET cycle, had a
history of recurrent miscarriage – three previous embryo transfers had failed to
implant. There is a known elevated risk of miscarriage with the presence of TPOAb
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[244]. In addition, this woman had also been tested as heterozygote for the MTHFR
677 C>T (A222V) and MTHFR 1298 A>C (E429A) mutations which are also known risk
factors for recurrent miscarriage [245]. The other woman who undertook OI
treatment, had only one failed cycle previously, but also had PCOS which is associated
with an increased prevalence of autoimmune thyroiditis [246, 247].
Although only a small number of women tested positive for TPOAb in this study, each
patient’s medical history was a clear indicator of the association between reproductive
disorders and thyroid dysfunction.
7.3.6 Thyroid Reference Ranges in Early Pregnancy
A woman’s thyroid status during pregnancy is difficult to establish without gestational
age-specific reference ranges. In addition to maternal thyroid changes during gestation
[224], there are significant differences in reference intervals between immunoassays
[248-250], highlighting the need for further research to establish reliable common
limits to correctly diagnose thyroid dysfunction in pregnancy.
There is a current paucity of literature that examines thyroid reference ranges prior to
gestation week 9, and most research is performed even later in the first trimester.
Therefore the data obtained from this present study is invaluable, providing reliable
thyroid reference ranges from gestation weeks 4 to 6.5.
TSH concentrations were log transformed to normalise the data before determining
appropriate reference ranges. The mean for each gestation week fell below 1.5mU/L,
with the highest upper range of 2.45mU/L at gestation week 4, which is just below the
normal first trimester upper range of 2.5mU/L recommended by the Guidelines of the
American Thyroid Association [92]. 32.9% of patients in this study at one point during
their pregnancy had at least one TSH measurement >2.5mU/L and 7.1% of patients had
at least one measurement >4.0mU/L. Elevated TSH levels did not affect pregnancy
outcome. However, levels that are considered “normal” during this time are constantly
debated. Mean thyroid hormones levels in this study did not differ between non-
pregnant (gestation week 0) and early pregnancy (up to gestation week 7), however
there were significant differences between some gestational weeks during early
pregnancy. It is known that first trimester thyroid function is different to pre-
pregnancy, in particular a decrease in TSH, which is the same trend observed in the
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present study. Median levels of TSH in this study (1.34mU/L) were higher than
published levels later in the first trimester (0.89mU/L) [250] indicating that levels of
TSH would likely continue to decrease in later first trimester weeks and therefore
would end up being significantly different to non-pregnant levels.
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8 Summary
8.1 Clinical Relevance and Implications
The benefit of this present study was the repeated measures of hormones in the same
patients, in contrast to using different groups of subjects in a cross sectional study
design. The ability to directly compare each of the hormone levels within the same
individual over time resulted in the discovery of unique changes in very early
pregnancy that would otherwise remain unnoticed. Analysing serial samples in batches
minimised between-assay variability in measurements. Precision of each of the
hormone assays was useful to determine the reliability of results at varying
concentrations.
No other study has investigated AMH changes prior to gestation week 7. This study has
further contributed to the understanding of the mechanisms of AMH, by showing the
patterns of change during pregnancy and the relationships this hormone has with
other factors. In particular, there seems to be two distinct groups of women that show
either an increase or decrease in AMH levels during pregnancy. Significant differences
in AMH levels during the menstrual cycle and also in nonviable pregnancies were
observed, which raises the issue that AMH levels are not constant and should be
measured more than once in an individual when assessing their ovarian reserve. This
would be particularly useful information for clinicians when diagnosing a patient with
infertility and would be helpful when determining the best treatment. This study found
that AMH is in fact variable and a gradual and consistent increase or decrease in levels
did not impact on the viability of the pregnancy. This is an important reassurance to
clinicians that AMH trending up or down should not cause alarm. In contrast, very
erratic levels of AMH may need to be further considered in the context of a
pregnancy‘s viability.
This study has also provided important thyroid reference range data for a critical time
in pregnancy, when the growing fetus relies on maternal levels of thyroxine for
neurocognitive development. We established that the average non-pregnant levels of
all thyroid markers (gestation week 0) did not predict the levels during early pregnancy
(from gestation week 4 to 6.5), and there were significant differences noted between
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multiple time points during pregnancy for fT3 and TSH. It may be helpful for clinicians
to be aware that thyroid levels may change week by week when observing reference
ranges, despite all upper limits still falling within the “normal” range during the first
trimester.
8.2 Limitations
A limitation of this present study was that a number of patients presented with varying
fertility issues including PCOS, which was not accounted for in the analysis. Therefore
the results of this study may not reflect a healthy pregnant population.  Patients were
also not grouped by ethnic background, and some authors have noted that ethnicity
may affect AMH levels. The number of samples were large enough to accurately
determine statistical significance in each of the analyses, except when comparing the
hormones in viable vs nonviable pregnancies, when the patient numbers in the
nonviable group were low and affected the power of calculations.
8.3 Future Research
There is not a lot known about AMH in pregnancy and therefore the main focus of this
study was to document changes in AMH using in-depth analyses. Since there is not a
lot of literature to explain the dynamics of AMH during pregnancy this study did not
provide an in-depth discussion of what factors may be causing these changes. The fact
that there are significant changes in AMH during early pregnancy is a novel and
interesting discovery in itself, and definitely merits future studies to investigate
possible causes.
The patterns of AMH change should be further investigated in a cohort of pregnant
women that have not undertaken ART and do not present with any reproductive
disorders. A larger cohort of women that experience recurring miscarriages may be
worthwhile to validate the pattern of AMH change observed in this study in nonviable
pregnancies. Other factors which may be contributing to the changes in AMH during
early pregnancy need further investigation. A study to further examine AMH stability in
serum samples frozen at -20°C over varying extended storage periods would be also be
useful.
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Medication Key
Common Name Abbreviation Chemical name Units Administered Use Company
Aspirin ASP Acetylsalicylic acid mg Oral tablet Anticoagulant Apotex
Cetrotide CET Cetrorelix acetate µg Injection GnRH antagonist Merck Serono
Clexane CLX Enoxaparin sodium mg Injection Prevention of venousthromboembolism Sanofi-Aventis
Clomid CLO Clomiphene citrate mg Oral tablet Synthetic ovulationstimulant Sanofi-Aventis
Crinone CRI Progesterone mg Vaginal gel Pregnancy support Merck Serono
Doxycycline ABS Doxycycline mg Oral tablet Antibiotic Sandoz
Elonva ELO Corifollitropin alfa mg Injection Controlled ovarianhyperstimulation
Merck Sharp &
Dohme
Endometrin EPS Progesterone mg Pessaries Pregnancy support Ferring
Gonal-F GON Follitropin alfa IU Injection Controlled ovarianhyperstimulation Merck Serono
Lucrin LUC Leuprorelin acetate mg Injection GnRH agonist AbbVie
Luveris LUV lutropin alfa IU Injection LH Merck Serono
Menopur MEN human menopausalgonadotrophin IU Injection
Controlled ovarian
hyperstimulation Ferring
Oral Contraceptive
Pill OCP
Ethinyloestradiol/
Drospirenone
µg/
mg Oral tablet
Regulate cycle and
time ovulation Bayer
Orgalutran ORG Ganirelix mg Injection GnRH antagonist Merck Sharp &Dohme
Oripro PPS Progesterone mg Pessaries Pregnancy support Merck Serono
Ovidrel OVI Choriogonadotropinalfa µg Injection
Superovulation egg
trigger Merck Serono
Panafcortelone PRD Pregnisolone mg Oral tablet Anti-rejection
Aspen
Pharmacare
Australia
Pregnyl PRE Choriogonadotropinalfa IU Injection Final egg release
Merck Sharp &
Dohme
Progynova PRO Oestradiol valerate mg Oral tablet Hormonereplacement therapy Bayer
Proluton PTN Progesterone mg Injection Pregnancy support Bayer
Provera PRV Medroxyprogesterone acetate mg Oral tablet Induce a bleed Pfizer Australia
Puregon PUR Follitropin alfa orbeta IU Injection
Controlled ovarian
hyperstimulation
Merck Sharp &
Dohme
Scitropin SCI Somatropin mg Injection
Recombinant human
growth hormone for
egg quality
SciGen Australia
Synarel SYN Nafarelin mg Nasal spray GnRH agonist Pfizer Australia
Patient ID Cycle Medications taken by each patient
37 AIH PUR50 OVI250 OVI60
52 AIH GON50 OVI250 OVI60 PPS400
60 AIH GON62.5 OVI250 OVI60 PPS400
76 AIH GON50 OVI250 OVI60
78 AIH GON25 OVI250 OVI60 PPS400
82 AIH GON25 OVI250 OVI60 PPS400
85 AIH GON25 OVI250 OVI60 PPS200
4 FET GON50 OVI250 OVI60 PPS600
5 FET PRO16 PPS1200 PTN25 CLX20 ASP100
7 FET GON50 OVI250 OVI60 PPS400
11 FET GON75 OVI10 ABS100 OVI250 PRD10 PPS600
16 FET OCP3/30 PRO16 PPS1200 PTN25
19 FET GON37.5 OVI250 PPS400
21 FET GON25 OVI250 OVI60
26 FET GON37.5 OVI250 PRD10 OVI60 PPS400 CLX40
27 FET GON62.5 OVI250 OVI60 PPS400
28 FET GON25 OVI250 OVI60
32 FET GON37.5 OVI250 OVI60 PPS400
34 FET PRO8 PRD10 PPS2400 PTN25 CRI180 CLX40 ASP100
38 FET PRO16 PPS800 PTN25 CRI90
39 FET GON37.5 OVI250 PRD10 OVI60 PPS400 CLX20 ASP100
46 FET GON50 OVI250 PPS400
51 FET PUR25 OVI250 OVI60 PPS200
55 FET GON37.5 OVI250 OVI60 PPS400
57 FET PRO16 ABS100 PPS1200 PTN25 CLX20 ASP100
58 FET GON37.5 OVI250 OVI60 PPS400
61 FET GON50 ABS100 OVI250 PRD10 PPS400 CLX40
64 FET PRO10 PPS800 PTN25
65 FET GON50 OVI60 PPS600
68 FET GON50 OVI250 OVI60
69 FET GON25 OVI250 OVI60 PPS400
71 FET GON50 OVI250 OVI60 PPS400
8 ICSI SYN400 PUR300 OVI500 PPS400
15 ICSI ORG250 GON150 OVI10 OVI500 OVI60 PPS400
17 ICSI ORG250 GON125 OVI10 OVI500 PPS400
22 ICSI CET250 GON175 LUV75 OVI500 PPS400
23 ICSI ORG250 GON150 OVI500 PPS400
24 ICSI CET250 GON400 OVI10 SCI40 PRE10000 PRD10 OVI60 PPS600 CLX40
29 ICSI LUC10 PUR200 OVI500 PPS400
31 ICSI ORG250 GON200 OVI10 PRE10000 PPS400
33 ICSI SYN400 PUR200 OVI20 OVI500 PPS200
35 ICSI OCP3/30 LUC10 ORG250 GON175 OVI10 PRE10000 PPS400
36 ICSI ORG250 PUR100 OVI10 PRE10000 PPS400
41 ICSI SYN400 PUR175 OVI20 ABS100 PRE10000 PRD10 PPS400 ASP100
50 ICSI ORG250 PUR200 OVI500 PPS400
54 ICSI ORG250 GON125 OVI10 OVI500 PPS400
59 ICSI SYN400 GON200 OVI10 PRE10000 PPS400
70 ICSI GON450 OVI10 PRE10000 PRD10 PPS400 CLX20 ASP100
72 ICSI SYN400 GON200 OVI500 PPS400
10 IVF OCP3/30 LUC10 GON175 LUV75 OVI500 PPS400
13 IVF ORG250 GON150 OVI500 PPS400
14 IVF SYN400 PUR300 OVI500 PRD10 PPS400
45 IVF ORG250 MEN150 OVI500 PRD10 PPS400 CLX20 ASP100
56 IVF LUC10 GON150 OVI500 PPS400 PRV5
66 IVF ORG500 GON200 PRE10000 PPS400
67 IVF LUC10 SYN400 GON300 OVI500 PPS400
79 IVF SYN400 PUR250 ABS100 PRE10000 CRI90 CLX20 ASP100
1 OI GON25 OVI250 OVI60 CLX20 ASP100
2 OI GON100 OVI250 PPS800 CRI90
6 OI CLO100 OVI250 OVI60
18 OI CLO50 OVI250 OVI60
20 OI CLO50 OVI250 OVI60 PPS200
30 OI CLO5 OVI250 OVI60 PPS200
43 OI GON37.5 OVI250 OVI60 PPS400
44 OI GON62.5 OVI250 OVI60 PPS400 CLX20 ASP100
47 OI GON50 OVI250 OVI60 PPS200
48 OI CLO100 OVI250 OVI60
49 OI CLO2.5 OVI250 OVI60
53 OI CLO50 OVI250 OVI60
83 OI GON50 OVI250 PPS400
3 TRACK None
9 TRACK None
12 TRACK None
25 TRACK PPS200
40 TRACK None
42 TRACK PPS200
62 TRACK PPS200
63 TRACK PPS200
73 TRACK PPS200
74 TRACK None
75 TRACK PPS200
77 TRACK PPS400
80 TRACK PPS200 CLX20
81 TRACK None
84 TRACK None
